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Feline infectious peritonitis (FIP) is an untreatable and terminal disease of cats 
caused by systemic infection with a feline coronavirus termed feline infectious 
peritonitis virus (FIPV).  This thesis investigates the cellular entry of FIPV in order to 
discover targets which may be of therapeutic value in treating this disease.   This 
thesis demonstrates that FIPV utilizes the lectin DC-SIGN to enhance cellular uptake.  
This is significant because macrophages and dendritic cells, which express DC-SIGN 
at high levels, are infected by FIPV to initiate the disease process.  This thesis also 
shows that FIPV activates the p38 MAPK signaling pathway in infected cells, and that 
this induces the overproduction of pro-inflammatory cytokines observed in cats with 
FIP.  Finally this thesis demonstrates that feline coronaviruses require cathepsin 
cysteine proteases during entry to cleave and activate the viral spike protein.  In 
addition, specific proteases are preferred over others depending on the pathogenicity 
of the virus.  It is also shown that certain molecular inhibitors of cysteine proteases 
can block viral infection in primary feline cells, presumably by preventing cleavage of 
the spike protein during viral entry.  These data highlight new therapeutic strategies 
for the treatment of FIP which will be discussed in the conclusion. 
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1.1  Feline Infectious Peritonitis 
 Feline infectious peritonitis (FIP) is a disease of cats with a spectrum of 
pathological outcomes, all of which are lethal.  FIP was first described as a disease in 
the 1960’s (26), however later analysis of necropsy records showed that it first 
appeared in cats during the previous decade (51).  The causative agent of FIP is a 
coronavirus designated as feline coronavirus (FCoV) (75, 81).   There are two 
dominant manifestations of FIP in cats.   The more common wet (effusive) form is 
characterized by the accumulation of fluid in the peritoneal or thoracic cavity due to 
pyrogranulomatous endothelial lesions (75).  The dry (non-effusive) form is often 
characterized by granulomatous lesions in the central nervous system (CNS) or eyes 
leading to neurological and ocular symptoms (42).  However lesions in cats with the 
dry form of FIP have also been observed in a variety of other tissues (54).  
Lymphopenia, enteritis, fever, weight loss and lethargy are common symptoms in cats 
with both forms of FIP (1). 
   
1.2  Virus Classification 
Coronaviruses are enveloped and contain a single-stranded positive-sense 
RNA (+ssRNA) genome (33).  They are divided into five groups (1a,1b,2a,2b,3) 
(Table 1.1) (20).  Feline coronaviruses are members of group 1a, and most closely 
related to canine coronavirus (CCoV) and porcine transmissible gastroenteritis virus 
(TGEV) suggesting a common origin (27).  Feline coronaviruses are further 
differentiated into serotype 1 (FCoV-1) and serotype 2 (FCoV-2) based on spike 
protein homology (43).  Serotype 1 feline coronaviruses make up approximately 80% 
of field isolates, and are more closely related to serotype 1 canine coronavirus (CCoV-
1) (37).  Serotype 2 feline coronaviruses are less common, but may be more likely to 
cause  FIP  (36).   They  are  more  closely  related  to  serotype  2  canine  coronavirus  
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 Table 1.1 Classification of coronaviruses. Significant coronaviruses representing the 
five groups (1a, 1b, 2a, 2b, 3) are listed.  Also shown are major determinants of viral 
tropism (when known): the host-cell receptor and proteolytic enzymes that have been 
shown to cleave and activate the spike (S) protein.  Aminopeptidase N (APN), 
angiotensin converting enzyme 2 (ACE2), carcinoembryonic antigen-related cell 
adhesion molecules (CEACAM), elastase (E), trypsin (T), furin (F), cathepsin B (B), 
cathepsin L (L). 
 
 
Coronavirus Host Receptor S Cleavage
    
Group 1a    
Feline coronavirus (type 1) Cat ? F, B (60) 
Feline coronavirus (type 2) Cat APN (71)   B, L (61) 
Canine coronavirus (type 1) Dog ? ? 
Canine coronavirus (type 2) Dog APN (71) B, L (60) 
Transmissible gastroenteritis virus Pig APN (71) B, L (60) 
Ferret coronavirus Ferret ? ? 
    
Group 1b    
Human coronavirus NL63 Human ACE2 (23) ? 
Human coronavirus 229E Human APN (80) T, L (30) 
Bat coronavirus (Trinidad) Bat ? ? 
Porcine epidemic diarrhea virus Pig APN (34) ? 
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 Table 1.1 (continued) 
 
Coronavirus Host Receptor S Cleavage
    
Group 2a    
Human coronavirus OC43 Human Sialic acid (74) ? 
Human coronavirus HKU1 Human ? ? 
Porcine hemagglutinating 
encephalomyelitis virus 
Pig Sialic acid (64) ? 
Bovine coronavirus Cow Sialic acid (64) ? 
Murine hepatitis virus Mouse CEACAM (25) T (16), F (16), 
B (58) 
    
Group 2b    
Severe acute respiratory 
syndrome (SARS) coronavirus 
Human ACE2 (35), 
DC/L-SIGN (40) 
E (41), T (41),   
B (28), L (28) 
Bat-SARS coronavirus Bat ? ? 
    
Group 3    
Infectious bronchitis virus Chicken Sialic acid (77) F (79), T (79)  
Turkey coronavirus Turkey ? ? 
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(CCoV-2) and TGEV (37).   
In addition to group and serotype, feline coronaviruses are divided into two 
biotypes based on their pathological outcome (53).  Members of the nonpathogenic 
biotype are classified as feline enteric coronavirus (FECV), and are common 
throughout the world's population of domesticated and wild cats (55).  FECV 
replicates mostly in the intestinal epithelial cells of the gut, and causes mild to 
unapparent enteritis (52).  In contrast, feline coronaviruses that cause FIP can 
efficiently replicate in the immune cells of their host (67).  These highly pathogenic 
viruses cause a lethal systemic infection, and are classified as the feline infectious 
peritonitis virus (FIPV) biotype (53). 
   
1.3 Replication and Assembly 
 The feline coronavirus genome consists of an unsegmented 29kb +ssRNA 
which is translated by ribosomes after cellular entry (47). It codes for the viral 
replicase (1a/1b), four structural proteins (spike, envelope, membrane and 
nucleocapsid), and five accessory proteins (3a, 3b, 3c, 7a and 7b) (62).  The viral 
replicase is activated by intramolecular proteolytic processing, and then proceeds to 
polymerize negative-sense copies of the viral genome (31).  These serve as templates 
for the production of full length (genomic) and partial length (subgenomic) viral 
+ssRNA (14).   Subgenomic and genomic +ssRNA are translated to produce the viral 
structural and accessory proteins (62).  Genomic copies are also packaged into newly 
assembled viral particles (Figure 1.1) (8, 45). 
 The viral structural proteins spike, envelope and membrane are produced and 
incorporated into the membrane of the host cell endoplasmic reticulum (54).  The 
nucleocapsid protein binds newly synthesized viral genomes and the membrane 
protein  (44).   Fully  formed  complexes  bud  into  the  ER  to  become  internal  viral  
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Figure 1.1  Diagram of coronavirus entry and replication.  Spike protein on the 
surface of the viral particle binds a specific host receptor, and then mediates entry of 
the viral genome into the cell.  Ribosomes translate the viral replicase from the 
+ssRNA viral genome.  The replicase polymerizes -ssRNA templates which are used 
to make genomic +ssRNA which are packaged into new viral particles, and partial 
length subgenomic +ssRNA which is used as a template for the production of viral 
structural proteins and accessory proteins.  
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Figure 1.2 Diagram of coronavirus assembly.  Viral structural proteins (membrane, 
spike, envelope, and nucleocapsid) are produced from subgenomic +ssRNA.  
Membrane, spike and envelope are membrane-bound proteins that are incorporated in 
the ER membrane.  Nucleocapsid is a soluble protein which binds full length genomic 
+ssRNA.  Nucleocapsid interacts with the membrane-bound structural proteins, and 
the entire complex buds into the ER lumen.  These newly formed viral particles are 
then secreted through the Golgi and exocytosed from the cell.   
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particles (49).  These particles are trafficked through the Golgi and released from the 
cell by exocytosis (Figure 1.2) (66).   
             
1.4 Spike Protein 
 The coronavirus spike protein is a membrane-bound glycoprotein expressed on 
the surface of viral particles responsible for host cell receptor binding and virus-cell 
membrane fusion (17).  The spike protein is categorized as a class I viral fusion 
protein and has characteristics in common with other class I viral fusion proteins such 
as influenza virus hemagglutinin (HA), retrovirus envelope (Env) and paramyxovirus 
fusion (F) (7, 12).  The spike protein is divided into two domains designated as S1 and 
S2.  S1 is responsible for host cell receptor binding, while S2 facilitates virus-host 
membrane fusion to facilitate cellular entry (3).  Class I viral fusion proteins are 
“primed” for fusion by proteolytic cleavage, and then “activated” by receptor binding, 
low pH, or a combination of the two (32).   
The spike proteins of group 2a coronaviruses (e.g. MHV-1) and group 3 
coronaviruses (e.g. infectious bronchitis virus (IBV)) are cleaved by furin or furin-like 
enzymes in the secretory pathway during viral particle assembly and trafficking (4, 
16).  This occurs at specific sites containing the amino acids lysine or arginine, present 
at either the S1/S2 boundary, or at a conserved site within the S2 domain (4, 79).  In 
contrast, the spike proteins of group 1a/1b and 2a coronaviruses remain uncleaved 
during assembly, except in a few cases (9, 57).  It has recently been shown that some 
group 1a coronaviruses (e.g. human coronavirus 229E (HCoV-229E)) and group 2b 
coronaviruses (e.g. severe acute respiratory syndrome associated coronavirus (SARS-
CoV)) are cleaved after assembly, either by trypsin- or elastase-like proteases in the 
extracellular space (76), or by cysteine proteases in the host cell endocytic pathway 
(28, 30).     
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1.5 Cellular Entry  
 Cellular entry commences when the spike protein on the surface of a viral 
particle binds to the extracellular domain of specific membrane-bound receptors on the 
host cell surface (65).  Aminopeptidase N has been identified as the receptor for many 
group 1a and 1b coronaviruses, including FCoV-2, CCoV-2, TGEV, HCoV-229E and 
porcine epidemic diarrhea virus (PEDV) (34, 70, 71).  FCoV-1 has been suggested to 
use a different unidentified receptor (11).  The other exception is group 1b human 
coronavirus NL63 (HCoV-NL63) which utilizes angiotensin converting enzyme 2 
(ACE2) instead of APN (23).  The receptor for group 2a coronavirus MHV is 
CEACAM (25).  Group 2b bovine coronavirus (BCoV) and porcine hemagglutinating 
encephalomyelitis virus (PHEV) utilize sialic acid (64).  The group 2b SARS-CoV 
utilizes ACE2 as its receptor (35).  The dendritic cell specific ICAM-3-grabbing 
nonintegrin (DC-SIGN) and liver/lymph node specific (L-SIGN) have also been 
shown to enhance entry of SARS-CoV (40).  Both sialic acid and heparin have been 
reported to play a role in the entry of the group 3 coronavirus IBV (39, 77).   
After receptor binding, a virus-host membrane fusion event occurs either at the 
cell surface, or after endocytosis of the viral particle (65).  For many coronaviruses, it 
is still unclear which mechanism of entry is utilized.  Recent evidence suggests that 
coronaviruses may have the ability to utilize either pathway dependent on the host 
environment.  For example, SARS-CoV enters a host cell via endocytosis and 
cathepsin L-mediated spike protein cleavage (28); however if this pathway is blocked, 
the virus can enter by a trypsin- or elastase-mediated event the cell surface instead 
(41).   
In addition to receptor binding, many coronaviruses are dependent on low-pH 
for cellular entry such as IBV (6), MHV (46) and SARS-CoV (28).  IBV requires low 
pH for spike protein fusion activation, as is the case for other class I viral fusion 
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proteins like influenza HA (6). However, in the case of SARS-CoV, the cathepsin L 
mediated spike protein cleavage is the low-pH dependent step, not fusion itself (28).    
 
1.6  Cathepsin B and L 
 Cathepsins are a group of cysteine proteases within the papain family of 
proteases, which also includes papain and related plant proteases (2).  Cathepsins are 
localized mainly to the endocytic pathway of cells, but are also secreted and found at 
the cell surface (29).  Most cathepsins possess endopeptidase activity, although some 
such as cathepsin B (catB) can also act as an exopeptidase (38).  Some cathepsins have 
specific amino acid motifs which are required for cleavage to occur, whereas others 
are more promiscuous.  Cat B prefers to cleave where the P1 position is an arginine or 
lysine (5).  Cathepsin L (catL) prefers to cleave at an arginine or lysine as well, but 
also requires the P2 position be a bulky hydrophobic amino acid (5).  CatB and catL 
are essential for entry of viruses such as reovirus (13), hendra virus (50), nipah virus 
(10) and coronaviruses such as SARS-CoV (28) and MHV-2 (58).  A number of small 
molecule inhibitors have been created which target either one (e.g. CA-074Me inhibits 
catB) or all cathepsins (e.g. E-64-d) in vitro and in vivo with no reported toxicity in 
mice (72). 
 
1.7 Transmission 
 FECV is shed at high titers in the feces of infected cats and is transmitted 
efficiently via the oral-fecal route (52).  However cases of FIP are usually isolated 
incidents among a population suggesting that FIPV is not efficiently transmitted (54).  
An important observation was made when FECV and FIPV isolates from the same 
geographic area and serotype were shown to be more closely related to each other (98-
99% homology) than to analogous isolates from different geographic regions (80-90% 
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homology), suggesting that separate strains of FECV and FIPV do not exist 
independently of each other (73).  The currently accepted model claims that FECV 
infects a young naïve host via fecal-oral transmission, and is usually cleared by an 
appropriate immune response (52). However, an ineffective immune response may 
lead to the establishment of a persistent infection of FECV in the gut (54).  The low 
fidelity viral replicase causes the production of mutant viruses during a persistent 
infection, some of which have the ability to infect immune cells and are now referred 
to as FIPV (67).  Specific mutations in the spike protein and accessory protein 3c have 
been suggested to play a role in the conversion of FECV to FIPV, however the 
mechanism has yet to be described (54, 63). 
 
1.8  T-cell Activation  
 In addition to mutations in the virus, the ability of FECV to convert to FIPV 
appears to depend on the immune system of the host.  The accepted model suggests 
that the specific type of T-cell activation in the host defines the outcome of the disease 
(54).  If the host mounts a “cell-mediated” type 1 T-helper cell (Th1) immune 
response, then the initial FECV infection is eliminated.  A persistent infection of 
FECV may become established in gut epithelial cells if the immune system mounts an 
“antibody-mediated” type 2 T-helper cell (Th2) response; a mix of Th1 and Th2 
responses; or a compromised Th1 response (54).  During a persistent FECV infection, 
FIPV mutants may arise and start to replicate in immune cells.  If the host then mounts 
a potent Th1 response, the virus can be eliminated from infected cells and disease is 
averted.  If the host instead mounts a Th2 antibody-mediated response, it actually 
enhances the disease by a process termed antibody-dependent (back off ADE) 
enhancement (ADE) (48).  Antibodies usually bind viral particles and target them for 
destruction by immune cells such as macrophages, however FIPV is able to avoid 
11 
 
destruction and hijack the very cell attempting to destroy it (24).  A Th2 response also 
causes the accumulation of virus-antibody complexes on endothelial tissue, leading to 
the extreme vasculitis seen in cats with the wet form of FIP (56).  If the host responds 
to FIPV with a mix of Th1 and Th2 responses, or a compromised Th1 response, FIPV is 
only partially cleared from immune cells, and establishes a persistent infection in 
immune cells and certain tissues.  This results in the non-effusive dry form of FIP, 
which may progress more slowly (54).  The type of T-cell activation also dictates 
which cytokines are produced in response to infection (59).  Cats suffering from FIP 
have been shown to produce high levels of Th2-associated pro-inflammatory cytokines 
such as tumor necrosis factor alpha (TNFα), interleukin-1 beta (IL-1β) and interleukin-
6 (IL-6), all of which are indicators of a poor outcome (18, 19, 68). 
  
1.9 Current Treatments 
 There is no current recommended treatment for FIP, and a cat with a confirmed 
diagnosis is usually euthanized depending on the severity and progression of the 
disease (21).  The use of immunosuppressant’s such as glucocorticoids and 
cyclophosphamide have been reported to slow disease progression, but do not prevent 
a fatal outcome (22).  Vaccines against FCoV have proven ineffective at preventing 
FIP, in some cases actually enhancing disease progression (69).  A vaccine is currently 
marketed that confers protective immunity against FCoV-2, but cannot be 
administered until after 16 weeks when most kittens are already seropositive (78).  In 
addition it does not cross-protect against the more common FCoV-1 and is therefore 
not recommended by the American Association of Feline Practitioners Feline Vaccine 
Advisory Panel (15).          
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2.1  Summary 
The entry and dissemination of viruses in several families can be mediated by 
C-type lectins such as DC-SIGN. We showed that entry of the serotype II feline 
coronavirus strains feline infectious peritonitis virus (FIPV) WSU 79-1146 and DF2 
into nonpermissive mouse 3T3 cells can be rescued by the expression of human DC-
SIGN (hDC-SIGN) and that infection of a permissive feline cell line (Crandall-Reese 
feline kidney) was markedly enhanced by the overexpression of hDC-SIGN. 
Treatment with mannan considerably reduced infection of feline monocyte-derived 
cells expressing DC-SIGN, indicating a role for FIPV infection in vivo. 
 
2.2  Introduction 
The entry of coronaviruses (CoVs) is mediated by a primary receptor, which in 
many cases has been well characterized (29).  Aminopeptidase N (APN, or CD13) acts 
as a primary receptor for the entry of serotype II feline coronaviruses (FCoVs) in both 
feline infectious peritonitis virus (FIPV) and feline enteric coronavirus (FECV) 
biotypes (10, 29), as well as in transmissible gastroenteritis virus and human CoV 
strain 229E (HCoV-229E) (27). In addition to having a primary receptor, it is 
becoming increasingly clear that coronaviruses also make use of a variety of 
nonspecific receptors during entry, including sialic acid and C-type lectins (29). 
Notably, severe acute respiratory syndrome CoV was shown to utilize liver/lymph 
nonspecific ICAM-3-grabbing nonintegrin (L-SIGN/CD209L) as a receptor in cis (11, 
17), possibly in combination with a specific receptor, ACE2. Severe acute respiratory 
syndrome CoV also interacts with dendritic cell (DC)-specific ICAM-3- grabbing 
nonintegrin (DC-SIGN/CD209) in cis (11), as well as with DC-SIGN and/or L-SIGN 
in trans (19, 30). L-SIGN and DC-SIGN have also been shown to promote the entry of 
HCoV-229E and HCoV-NL63, respectively (12, 16). 
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The utilization of C-type lectins as entry factors was first demonstrated for 
human immunodeficiency virus type 1 (1, 9), and it is now known that viruses in 
various families use DC-SIGN and/or L-SIGN for entry and dissemination, acting 
either in cis or in trans (3, 18). C-type lectins act as entry factors by preferentially 
recognizing viral glycoproteins containing high-mannose carbohydrate residues (3, 7). 
Compared to that in the human system, the use of C-type lectins as entry factors in 
nonhuman animal viruses has received little attention. A notable exception is the 
demonstration that feline immunodeficiency virus can specifically interact with human 
DC-SIGN and allow virus transmission to target cells in cis and in trans (6).  Based on 
this finding and the established role of L-SIGN/DC-SIGN for certain coronaviruses, 
we reasoned that FCoVs might be able to utilize C-type lectins as entry cofactors, with 
human DC-SIGN (hDC-SIGN) able to serve in this role. 
 
2.3  Results and Discussion 
To examine the possible role of hDC-SIGN in FIPV infection, we first 
analyzed the infection of mouse 3T3 cell lines stably expressing hDC-SIGN (NIAID 
AIDS Research and Reference Reagent Program) and compared it to that of 
nonpermissive wild-type 3T3 cells and permissive Crandall-Reese feline kidney 
(CRFK) cells (ATCC). Cells were infected with either serotype II FIPV strain WSU 
79-1146 (FIPV-1146) or FIPV-DF2 at a final concentration of 1 X 106 PFU/ml 
(multiplicity of infection (MOI) = 10 infectious units/cell), as determined by standard 
plaque assay of CRFK cells. The supernatants were collected, and the production of 
virus was determined at 24 h postinfection by 50% tissue culture infective dose assay 
of CRFK cells (Figure 2.1 A). As expected, 3T3 cells were not able to support FIPV 
infection; however, 3T3-hDCSIGN cells propagated the virus to a relatively high titer. 
The production of virus was approximately 2 log units lower than in permissive CRFK 
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cells. To confirm that productive infection was mediated specifically by the expression 
of hDC-SIGN, we transfected wild-type 3T3 cells with plasmid pcDNA3-DCSIGN 
(NIAID AIDS Research and Reference Reagent Program) to transiently express hDC-
SIGN. At twenty-four hours posttransfection, cells were infected with FIPV-1146 or 
FIPV-DF2 at a final concentration of 1 X 106 PFU/ml, and at 9 h postinfection, the 
cells were fixed. Cells were analyzed by immunofluorescence microscopy, using the 
anti-DC-SIGN monoclonal antibody (MAb) 120526 (an immunoglobulin G2a [IgG2a] 
isotype; NIAID AIDS Research and Reference Reagent Program) and the anti-FCoV 
nucleocapsid MAb 17B7.1 (an IgG2b isotype) (21) followed by isotype-specific 
secondary antibodies conjugated to Alexa Fluor 488 or Alexa Fluor 569 (Invitrogen). 
Infection of 3T3 cells by either FIPV-1146 or FIPV-DF2 strictly correlated with hDC-
SIGN expression (Figure 2.1 B). 
To examine how DC-SIGN might function in the context of FIPV infection of 
permissive cells, we created CRFK cells lines stably expressing hDC-SIGN.  CRFK or 
CRFK-hDCSIGN cells were infected with FIPV-1146 and FIPV-DF2 at a low MOI of 
0.01 infectious units/cell (1 X 103 PFU/ml). Cells were fixed at 6 h postinfection and 
analyzed by immunofluorescence microscopy after being stained with the IgG2a anti-
hDC-SIGN MAb 120526 and the IgG2b anti-FCoV nucleocapsid MAb 17B7.1. 
Infection of CRFK cells was markedly increased in CRFK-hDCSIGN cells (Figure 2.2 
A). To quantify the increase in infection following hDC-SIGN expression, the 
experiments were repeated with inocula of various amounts of FIPV (0.0005 to 1.0 
infectious units/cell), and images from at least three independent experiments (~1,000 
cells) were scored for infection. As shown in figure 2.2 B, the expression of hDC-
SIGN significantly enhanced infection of FIPV over a range of MOI values but with 
more-limited effects at the lowest and highest infectious doses. 
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To confirm that the enhancement of FIPV infection following DC-SIGN 
expression was specific, we infected CRFK or CRFK-DCSIGN cells with FIPV-1146 
and FIPV-DF2 at an MOI of 0.01 infectious unit/cell (1 X 103 PFU/ml) in the presence 
of mannan (50 mg/ml) as a competitor of DC-SIGN binding or in the presence of the 
anti-DC-SIGN MAbs 9E9A8 and 120526 (20 mg/ml; NIAID AIDS Research and 
Reference Reagent Program) (Figure 2.3). Both mannan and the two MAbs tested 
reduced FIPV infection to the control levels found in the absence of hDC-SIGN 
expression.  
Dissemination of FIPV in the cat relies on the ability of the virus to infect 
monocytes and macrophages (10). To examine the role of DC-SIGN in such in vivo 
situations, we isolated primary feline monocytes (23) and cultured them for 4 days in 
the presence of 20% fetal bovine serum. These cells were specifically recognized by 
the hDC-SIGN MAb DC6 (NIAID AIDS Research and Reference Reagent Program) 
indicating that they had undergone differentiation and were expressing DC-SIGN. We 
then treated these cells with either the MAb R-G-4 (200 mg/ml) to inhibit infection via 
the feline aminopeptidase N (fAPN) receptor (14) or with mannan (50 mg/ml). 
Monocytes were then infected with FIPV strains 1146 and DF2 at 1 X 106 PFU/ml 
(MOI = 10 infectious units/cell). Cells were fixed at 6 h postinfection and analyzed by 
immunofluorescence microscopy as described above. Compared to the untreated 
controls, both cells treated with R-G-4 and those treated with mannan showed a 
significant inhibition of FIPV infection, in both cases to around 15% of the level for 
the untreated cells (Figure 2.4). The addition of R-G-4 and mannan combined resulted 
in an almost complete blockage of FIPV infection (Figure 2.4). These data confirm 
previous reports that the blockage of fAPN with R-G-4 alone could not completely 
inhibit the infection of feline macrophages with serotype II FIPV (24) and suggest that 
both APN and DC-SIGN are important for infection in vivo. 
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Our studies show that the C-type lectin hDC-SIGN can rescue FIPV infection 
of nonpermissive cells and enhance infection of permissive cells, acting in cis. To 
date, we have not examined the use of hDC-SIGN in trans for FIPV infection in vivo. 
As the feline homolog of hDC-SIGN has not yet been cloned (6), the role of FCoV-
DC-SIGN interactions in cats remains to be demonstrated, and we have not examined 
serotype I FCoVs due to the difficulty in propagating these viruses in the laboratory. 
In our studies, we also examined human L-SIGN, which was able to rescue infection 
with FIPV-1146. However, as L-SIGN is as yet unreported except in humans, this was 
not examined further.  
It is interesting to note that both APN and DC-SIGN are localized to cell 
surface microdomains, or lipid rafts (2, 20), and that this localization is important for 
the function of DCSIGN during virus entry (2). This suggests that the colocalization of 
the two cell surface molecules may be a factor in successful FCoV entry into host 
cells. At present, however, little is known regarding the internalization pathway of 
FCoVs, although HCoV-299E (which uses a combination of APN and L-SIGN for 
entry) is believed to enter cells via cell surface microdomains that contain caveolin 
(20). Other likely factors in the successful use of DC-SIGN as an entry factor for 
coronaviruses are that viral spike proteins are heavily glycosylated and that the virus 
buds from the endoplasmic reticulum-Golgi intermediate compartment (13); the 
coronavirus spike protein is therefore likely to contain high-mannose sugars that 
would be a recognition site for C-type lectins (3, 4, 7).   
The majority of natural infections with FCoVs are classified as being in the 
FECV biotype and cause, at most,  mild enteritis in the intestinal epithelial tract.  It is 
believed that mutations within FECV viruses allow the dissemination  and  systemic  
spread  of  the  newly  generated  FIPV  biotype  viruses, and monocytes and 
macrophages are well established as cell types that act as a conduit for such systemic 
28 
 
spread (10). DC-SIGN is considered to be widely expressed in monocyte-derived 
macrophages which are thought to be the targets of FIPV infection in vivo (10), so in 
the course of our studies, we examined whether there were any differences in the 
utilization of DCSIGN by FIPV-1146 and the FECV biotype WSU 79-1638.  
However, we found no significant difference in the effects of hDC-SIGN expression 
between these two viruses, which suggests that any change in cell tropism between 
these viruses appears to occur at a post-receptor step of infection. At present, there is 
only limited information on the possible role of DCs in the dissemination of FIPV. 
With increased characterization of feline DCs (8, 25), it will be very interesting to 
explore these cells in the context of FIPV infection in cats. 
Although murine APN is not considered to support FIPV infection by itself 
(28), it remains possible that the entry of serotype II FCoV is mediated through a 
combination of DCSIGN and mouse APN. In this scenario, DC-SIGN would act as an 
entry cofactor, allowing for the use of mouse APN as a viral receptor. Alternatively, 
DC-SIGN may act an alternate receptor for FCoV rather than acting as an accessory 
factor. Such APN-independent entry of FIPV has been known for some time, based on 
Fc-mediated uptake of the virus into mouse macrophages in the presence of anti-S 
antibodies (5, 15, 22, 26). To address these possible models, hDC-SIGN was 
overexpressed in primary fibroblast cells from an APN knockout mouse and from a 
parental wild-type mouse (kindly provided by Renata Pasqualini and Wadih Arap, 
Anderson Cancer Center, Houston, TX). While overexpression of hDC-SIGN in wild-
type murine fibroblasts rescued infection by FIPV, it did not allow infection in APN 
knockout cells (data not shown), suggesting that DC-SIGN does not act as an alternate 
receptor for FIPV but rather acts as an entry cofactor. However, it cannot be ruled out 
that DC-SIGN may act as an independent FCoV receptor under certain conditions. 
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Figure 2.1 Expression of hDC-SIGN rescues FCoV infection of nonpermissive 
cells.  (A) 3T3, 3T3-DCSIGN, or CRFK cells were infected with FIPV-1146 or FIPV-
DF2 at a MOI of 10. Cells were rinsed and placed in fresh media after 2 h. At 24 h, 
cells and the supernatants were collected.  The production of virus was determined 
from at least three independent replicates of the experiment by 50% tissue culture 
infective dose (TCID50) assay. Error bars represent the standard deviations of the 
means. (B) 3T3 cells were transfected with pCDNA3-hDCSIGN. Twenty-four hours 
posttransfection, cells were infected with virus at a MOI of 10. Cells were fixed 9 h 
postinfection and stained for immunofluorescence microscopy with the IgG2a anti-
hDC-SIGN MAb 120526 and the IgG2b anti-FCoV nucleocapsid (anti-FIPV N) MAb 
17B7.1. 
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Figure 2.1 (continued) 
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Figure 2.2 Expression of hDC-SIGN enhances FCoV infection of permissive cells. 
(A) CRFK or CRFK-hDCSIGN cells were infected with FIPV-1146 or FIPV-DF2 at a 
MOI of 0.01. Six hours postinfection, cells were fixed and stained for 
immunofluorescence microscopy with the IgG2a anti-hDC-SIGN MAb 120526 and 
the IgG2b anti-FCoV nucleocapsid (anti-FIPV N) MAb 17B7.1. (B) CRFK or CRFK-
hDCSIGN cells were infected with FIPV-1146 or FIPV-DF2 at the indicated 
concentrations. Six hours postinfection, cells were fixed and stained for 
immunofluorescence microscopy with the anti-FCoV nucleocapsid MAb 17B7.1. 
Images from at least three independent experiments were captured and quantified. For 
quantification, ~1,000 cells from three independent replicates of each experimental 
condition were scored. Error bars represent the standard deviations of the means.  
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Figure 2.2 (continued) 
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Figure 2.3 Mannan and anti-hDC-SIGN MAbs block the enhancement of 
infection by FCoVs.  CRFK, CRFK-hDCSIGN, or CRFK-hDCSIGN cells pretreated 
with either mannan (50 µg/ml), anti-hDC-SIGN MAb 9E9A8 (20 µg/ml), or anti-
hDC-SIGN MAb 120526 (20 µg/ml) were infected with FIPV-1146 or FIPV-DF2 at a 
MOI of 0.01. Cells were fixed at 6 h postinfection and stained for 
immunofluorescence microscopy with the anti-FCoV nucleocapsid MAb 17B7.1. 
Images from at least three independent experiments were captured and quantified. For 
quantification, ~1,000 cells from three independent replicates of each experimental 
condition were scored. Error bars represent the standard deviations of the means. 
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Figure 2.4 Mannan inhibits FCoV infection of primary feline monocyte-derived 
cells expressing DC-SIGN. (A) Primary feline cells expressing DC-SIGN were 
pretreated with mannan (50 µg/ml), anti-fAPN MAb R-G-4 (200 µg/ml), or both in 
combination for 60 min before being infected with FIPV-1146 or FIPV-DF2 at a MOI 
of 10. Cells were fixed 12 h postinfection and stained for immunofluorescence 
microscopy with the anti-FCoV nucleocapsid (anti-FCoV N) MAb 17B7.1. (B) 
Images from at least three independent experiments were captured and quantified. For 
quantification, ~250 cells from three independent replicates of each experimental 
condition were scored. Error bars represent the standard deviations of the means. 
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Figure 2.4. (continued) 
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CHAPTER THREE 
 
DIFFERENTIAL ROLE FOR LOW PH AND CATHEPSIN-MEDIATED 
CLEAVAGE OF THE VIRAL SPIKE PROTEIN DURING ENTRY OF 
SEROTYPE II FELINE CORONAVIRUSES* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* A.D. Regan, R. Schraybman, R.D. Cohen, G.R. Whittaker.  2008.   Differential 
role for low pH and cathepsin-mediated cleavage of the viral spike protein during 
entry of serotype II feline coronaviruses.  Veterinary Microbiology.  132(3-4): 235-48. 
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3.1  Summary 
Feline infectious peritonitis (FIP) is a terminal disease of cats caused by 
systemic infection with a feline coronavirus (FCoV).  FCoV biotypes that cause FIP 
are designated feline infectious peritonitis virus (FIPV), and are distinguished by their 
ability to infect macrophages and monocytes. Antigenically similar to their virulent 
counterparts are FCoV biotypes designated feline enteric coronavirus (FECV), which 
usually cause only mild enteritis and are unable to efficiently infect macrophages and 
monocytes. The FCoV spike protein mediates viral entry into the host cell and has 
previously been shown to determine the distinct tropism exhibited by certain isolates 
of FIPV and FECV, however, the molecular mechanism underlying viral pathogenesis 
has yet to be determined. Here we show that the FECV strain WSU 79-1683 (FECV 
1683) is highly dependent on host cell cathepsin B and cathepsin L activity for entry 
into the host cell, as well as on the low pH of endocytic compartments. In addition, 
both cathepsin B and cathepsin L are able to induce a specific cleavage event in the 
FECV-1683 spike protein. In contrast, host cell entry by the FIPV strains WSU 79 
1146 (FIPV-1146) and FIPV-DF2 proceeds independently of cathepsin L activity and 
low pH, but is still highly dependent on cathepsin B activity. In the case of FIPV-1146 
and FIPV-DF2, infection of primary feline monocytes was also dependent on host cell 
cathepsin B activity, indicating that host cell cathepsins may play a role in the distinct 
tropisms displayed by different feline coronavirus biotypes.  
 
3.2  Introduction 
Coronaviruses are enveloped positive-stranded RNA viruses that replicate in 
the cytoplasm (31, 43). They have a distinctive set of club-shaped spikes on their 
envelope, comprised of the viral spike protein (S). The coronavirus S protein is a 
primary determinant of cell tropism and pathogenesis, being responsible (and 
44 
 
apparently sufficient) for receptor binding and fusion (19). Overall, the coronavirus S 
protein is categorized as a class I fusion protein (15) based on the presence of 
characteristic heptad repeats (4, 6, 29); as such it shows characteristic features of 
fusion proteins of influenza virus (HA), retroviruses (Env) and paramyxoviruses (F) 
for which there is extensive characterization at a structural and biophysical level (9). 
Many viral fusion proteins are known to be activated following cleavage by host cell 
proteases (27). This has been most extensively documented for orthomyxo- and 
paramyxoviruses. In the case of high pathogenicity avian influenza strains, mutations 
in the region of the cleavage site that modify it from a trypsin-like (monobasic) to a 
furin-like (polybasic) cleavage site allow systemic spread within the host and hence 
show drastically increased virulence (28). Although coronaviruses do show structural 
similarities to canonical class I fusion proteins, they appear to have significant 
differences in regard to the role of proteolytic cleavage for fusion activation (3).  
Coronavirus S proteins consist of two principal domains (S1 and S2), with S1 
responsible for receptor binding, and S2 mediating membrane fusion. In group 3 
coronaviruses (e.g., infectious bronchitis virus; IBV) there is ubiquitous cleavage of 
the S precursor protein to form the S1 and S2 subunits (5), with cleavage apparently 
carried out by furin. In group 2 viruses (e.g., for mouse hepatitis virus; MHV), S1/S2 
cleavage is variable (18).The ability to be cleaved at the S1/S2 boundary has been 
studied quite extensively for MHV-1 and 4 (58). While there is some correlation 
between S1/S2 cleavage and increased cell–cell fusion, in general there appears to be 
no direct link between syncytia formation (and by analogy S1/S2 protein cleavage) 
and pathogenicity (25). For the group 2MHV-2, the S protein remains uncleaved in the 
virus particle (45). For group 1 viruses (e.g., human coronavirus NL63 and feline 
coronavirus; FCoV), S1/S2 cleavage is not considered to occur (56), however, recent 
identification of a group 1 coronavirus with a furin-like motif at S1/S2 (44) suggests 
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this may not be the case with all group 1 members. Infection of cells by several 
coronaviruses has been shown to be sensitive to the presence of lysosomotropic 
agents, such as NH4Cl, which raise the pH of the endosome (2, 20, 24, 32, 35).  These 
data suggest a pH-dependent route of coronavirus entry through endosomes. In some 
cases (e.g., IBV and MHV-4), the coronavirus fusion reaction has been clearly shown 
to be triggered by low pH (8, 17), whereas in other cases, e.g., SARS-CoV, it is 
suggested that the low pH of the endosome is important for activation of cathepsin 
proteases that prime the fusion event (49), with fusion activation itself considered to 
be pH-independent. The classical cathepsins are cysteine proteases typically present 
within the endosome/lysosome system of host cells (1). While a role for cathepsins 
during entry of the non-enveloped reoviruses has been known for some time (16, 21), 
it has recently become apparent that the fusion proteins from several families of 
enveloped viruses can be cleaved by these proteases.  Such examples are the recently 
identified paramyxoviruses Hendra and Nipah (13, 39, 40), as well as Ebola virus (7, 
47, 48) and Moloneymurine leukemia virus (30). In the case of coronaviruses, SARS-
CoV and MHV-2 are thought to require cathepsin activation (26, 45, 49, 50), with 
cathepsin L predominantly involved in SARS-CoV entry, and cathepsin B mediating 
MHV-2 cleavage during virus entry.  For SARS-CoV, neither the site of cathepsin L 
mediated proteolysis nor the cleaved products produced are known, although for 
MHV-2 cathepsin B may cleave at the S1/S2 junction (45). Other coronaviruses such 
as MHV-4, HCoV-NL63 and IBV are not considered to be dependent on cathepsins 
(8, 26, 45).   
Feline infectious peritonitis (FIP) is a highly lethal systemic infection of cats 
caused by a group I feline coronavirus (FCoV) of the FIPV biotype (23, 36).  
However, under normal circumstances FCoVs cause only mild and often inapparent 
enteritis; in this case the virus is classified as the feline enteric coronavirus (FECV) 
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biotype (11, 23).  FCoVs can exist as either serotype I, or less commonly as serotype 
II, in which case the spike protein share extensive similarity with canine coronavirus 
(CCoV) and transmissible gastroenteritis virus (TGEV). Due to the relative ease of 
growth in cell culture, the serotype II FCoVs have been subject to some degree of 
molecular characterization. In particular, two strains of serotype II FCoV, WSU 79-
1683 and WSU 79-1146, have served as model viruses that cause either mild enteritis 
or FIP, respectively (41, 42). The viruses are thus referred to as FECV-1683 and 
FIPV-1146. In the ‘‘internal mutation’’ model of FIP it is believed that a process of 
mutation within an individual cat confers the ability of a FECV to infect macrophages 
and monocytes, and so allow systemic spread and become a virus that causes FIP (57). 
Despite extensive study, the genomic differences that determine whether an FCoV will 
behave as an FECV or an FIPV are still largely unknown (23). However, in the case of 
the serotype II FCoVs, mapping studies between the FECV-1683 and FIPV-1146 
spike proteins have determined critical domains involved in the switch to FIPV. 
Surprisingly, the S1 domain (receptor binding) domain is not important, and the 
critical region was mapped to the C-terminal part of the S2 (fusion) domain (46).   
In light of the recently determined involvement of cathepsins in activation of 
other coronavirus S proteins, we reasoned that the FCoV spike protein might be a 
target of cathepsins during virus entry, which might explain some of the unusual 
pathogenic properties of FIPV. Here we examined the entry pathway of feline 
coronaviruses and show a differential role for low pH and spike protein cleavage by 
cathepsin B and cathepsin L. 
 
3.3 Materials and methods 
Cell lines and primary feline monocytes Crandell–Rees feline kidney (CRFK) 
cells and feline fetal lung cells (AK-D) were obtained from the American Type 
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Culture Collection (ATCC). A-72 cells were provided by Dr. Colin Parrish (Cornell 
University, Baker Institute for Animal Health). Fc2Lu cells were provided by Dr. Ed 
Dubovi (Animal Health Diagnostic Center, New York State College of Veterinary 
Medicine, Cornell University). Primary feline monocytes were individually purified 
from the blood of three SPF cats (Liberty Research, Inc., Waverly, NY) using a 
standard Ficoll-paque gradient (GE Healthcare) as specified by the manufacturer. 
Monocytes were seeded in 24-well plates and allowed to attach to culture-treated glass 
coverslips overnight.  After washing, the purity of monocyte preparations was checked 
by immunofluorescence microscopy using the monocyte marker DH59B. CRFK, 
Fc2Lu, AK-D and A-72 cells were grown in the presence of 5% CO2 at 37 8C in 
RPMI-1640 media pH 7.4 supplemented with 10% fetal bovine serum (FBS), 2 mM 
glutamine, 100 U/ml penicillin and 10 mg/ml streptomycin. Monocytes were cultured 
under the same conditions except the media was supplemented with 20% FBS.   
FIPV WSU 79-1146 (FIPV-1146) was obtained from the ATCC. FECV WSU 
79-1683 (FECV-1683) and FIPV-DF2 were provided by Dr. Ed Dubovi (Animal 
Health Diagnostic Center, New York State College of Veterinary Medicine, Cornell 
University).  FIPV-1146 and FECV-1683 were grown in A-72 cells and FIPV-DF2 
was grown in CRFK cells, and supernatant collected after CPE was observed in 80% 
of cells. Supernatant was clarified by a low speed centrifugation step (1250 X g for 10 
min) and viral particles were then pelleted by centrifugation at 28,000 rpm in a SW28 
rotor (Sorvall) for 60 min.  Pellets were resuspended in either phosphate-buffered 
saline pH 7.4 for infection assays, or acetate buffer pH 5.0 for cathepsin cleavage 
assays. Virus titers were determined with TCID50 assays on CRFK cells, using 
standard techniques (22). Anti-FCoV nucleocapsid (17B7.1) (37) and spike (22G6.4) 
monoclonal antibodies were provided by Dr. Ed Dubovi (Animal Health Diagnostic 
Center, New York State College of Veterinary Medicine, Cornell University). The 
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monocyte marker antibody (anti-CD127a mAb DH59B) was obtained from Veterinary 
Medical Research & Development, Inc. (Pullman, WA).   
The cysteine protease inhibitor (2S,3S)-trans-epoxysuccinyl-L-leucylamido-3-
methylbutane ethyl ester loxistatin (E-64d), the cathepsin B inhibitor [L-3-trans-
(propylcarbamoyl)oxirane-2-carbonyl]-L-isoleucyl-L-proline methyl ester (CA074-
Me), the cathepsin K inhibitor 1-(N-benzyloxycarbonyl-leucyl)-5-(NBoc-
phenylalanyl-leucyl)carbohydrazide (Boc-l) and bafilomycin A1 were purchased 
Calbiochem (San Diego, CA). The cathepsin L inhibitor Z-Phe-Tyr(t-Bu)-
diazomethylketone (Z-FY-(t-Bu)-DMK) was purchased from Axxora (San Diego, 
CA).   
For growth assays, A-72 cells were seeded to 75% confluency on 24-well 
tissue culture-treated plates.  Cells were pre-incubated with specified treatments in 
serum-free media for 60 min before addition of virus to a final concentration of 106 
TCID50/ml. After 3 h, cells were washed and media replaced with fresh serum-free 
media. After 9 h, supernatant was collected and frozen at -80ºC until later 
determination of viral titer by TCID50 assay. For infection assays, cells were seeded to 
75% confluency on 24-well plates with tissue culture-treated glass coverslips. Cells 
were treated with inhibitors as specified, either 60 min before, or 60 min after the 
addition of virus. Virus was added to a final concentration of 106 TCID50/ml, which 
infected 20–50% of control cells under the conditions tested. 6 h post-infection, cells 
were fixed in 3% paraformaldehyde and stained with the anti-FCoV nucleocapsid 
mAb 17B7.1, essentially as described previously (Chu et al., 2006). Influenza virus 
and Sendai virus infection assays were performed as previously described (8). All 
assays were repeated at least three times and 8–15 widefield images were captured and 
quantified per experimental replicate. Cells were viewed on a Nikon Eclipse E600 
fluorescence microscope, and images were captured with a Sensicam EM camera and 
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IPLab software before transfer into ImageJ software (http:// rsb.info.nih.gov/ij/) for 
determination of infection frequency.   
Concentrated viral particles (1012 TCID50/ml) were suspended in acetate buffer 
pH 5.0. 50 ml of virus preparation was incubated with either purified cathepsin L 
(Calbiochem, San Diego, CA) or purified cathepsin B (Calbiochem, San Diego, CA) 
at a final concentration of 1 mM for 1 h at 37 8C, followed by the addition of 500 U 
PNGase F (New England Biolabs, Ipswich, MA) to allow differentiation of any 
multiply glycosylated species. SDS sample buffer was added and the reaction was 
heated at 95ºC before separation using a 4–20% SDS-PAGE gel at 200 V for 2 h. Gels 
were electroblotted to PVDF membrane, blocked with 5% bovine serum albumin and 
probed with the anti-FCoV spike protein mAb 22G6.4.  Membranes were developed 
using anti-mouse antibody linked to horseradish peroxidase (SouthernBiotech, 
Birmingham, AL) and ECL substrate (Pierce, Rockford, IL) and images captured 
using a Fujifilm LAS-3000 CCD camera. Western blot densitometry analysis of spike 
protein cleavage was performed using ImageJ software. Percent cleavage was 
determined by dividing pixel intensity of the cleaved spike protein band by total pixel 
intensity of the cleaved and uncleaved spike protein bands combined. 
 
3.4. Results and Discussion  
To determine the role of cysteine proteases in the life cycle of FIPV-1146 and 
FECV-1683, we first pretreated A-72 cells with the cell-permeable irreversible 
cysteine protease inhibitor E-64d, which non-selectively inhibits a range of cysteine 
proteases. Cells were then infected with either FIPV-1146 or FECV-1683. As a 
control, cells were infected with influenza virus, which is not believed to require 
proteolytic activation by cysteine proteases during entry. We collected cell 
supernatants at 9 h post-infection and assayed virus production by TCID50 assay. Pre-
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treatment with E-64d significantly reduced the production of both FIPV-1146 and 
FECV-1683 viral particles, as compared to control cells pre-treated with DMSO alone 
(Figure 3.1). As expected, E-64d had no effect on influenza virus infection.  To further 
investigate the potential roles of cathepsins in the growth of FIPV-1146 and FECV-
1683, cells were then pre-treated with specific inhibitors of cathepsin B (CA074-Me), 
cathepsin L (Z-FY-(t-Bu)-DMK) and cathepsin K (Boc1). As shown figure 3.1, the 
cathepsin B inhibitor considerably limited the production of both FIPV-1146 and 
FECV-1683. In contrast, the cathepsin L inhibitor had only a negligible effect on 
FIPV-1146; however, it greatly diminished the propagation of FECV-1683. Cathepsin 
K inhibitor had no significant effect on either virus (Figure 3.1). The specific 
cathepsin inhibitors also had no effect on influenza virus infection. These data indicate 
that both FIPV-1146 and FECV-1683 require cathepsin B activity for propagation, 
whereas FECV-1683 selectively requires cathepsin L activity. 
To establish if the effects of the cathepsin B and L inhibitors occurred during 
virus entry, A-72 cells were treated with five log dilutions of inhibitor either 60 min 
pre-infection, or 60 min post-infection, and infected with FIPV-1146 or FECV-1683. 
Cells were fixed 6 h post-infection, and infected cells were detected by 
immunofluorescence microscopy using the anti-FCoV nucleocapsid monoclonal 
antibody 17B7.1, and quantified (Figure 3.2). Pre-incubation with the specific 
cathepsin B inhibitor almost completely blocked infection by FIPV-1146, however, 
treatment after entry had no effect (Figure 3.2). Consistent with data from viral growth 
assays, the cathepsin L inhibitor had no effect on FIPV-1146 entry, except for some 
limited effect at the highest concentration tested (Figure 3.2 B). Pre-incubation with 
either cathepsin B or cathepsin L inhibitor both potently blocked infection by FECV-
1683, and again treatment after entry with either inhibitor had no effect. As a control, 
cells were treated with inhibitors and infected with influenza virus.  Infected cells 
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were fixed 6 h post-infection and detected by immunofluorescence microscopy with 
the anti-influenza nucleoprotein monoclonal antibody H19 (Figure 3.2). Neither the 
cathepsin B nor the cathepsin L inhibitor had an effect on influenza virus entry. 
Pretreatment with the cathepsin K inhibitor had no effect on the cellular entry of either 
FIPV-1146, FECV-1683 or influenza virus. These data show that the inhibitory effects 
of the cathepsin inhibitors are manifested during virus entry. 
Lysosomotropic agents such as NH4Cl and bafilomycin A are well established 
to disrupt the acidic environment of endocytic compartments. To assess the role of low 
pH during entry of FIPV-1146 and FECV-1683, A-72 cells were pre-treated with 
either NH4Cl or bafilomycin A1. We first assessed the effect of NH4Cl, a weak base 
that acts to neutralize the low pH of the endosome. Pre-treatment with 10 mM NH4Cl 
only partially inhibited entry of FIPV-1146 (approximately 20% inhibition), however, 
the same concentration almost completely blocked entry by FECV-1683 (Figure 3.3). 
Even following pre-treatment with 30 mM NH4Cl, FIPV-1146 entry was only 
partially blocked as compared to FECV-1683. As controls for these experiments, we 
used influenza virus and Sendai virus. Influenza virus is well established to require 
low pH to trigger its fusion mechanism and was completely inhibited by pre-treatment 
with 10 mM NH4Cl, analogous to the results obtained with FECV-1683 (Figure 3.3).  
Sendai virus is known to fuse at a neutral pH and accordingly showed no reduction in 
entry with cell pre-treated with NH4Cl (Figure 3.3).  We next assessed the effect of 
bafilomycin A1, an inhibitor of the vacuolar-type H+-ATPase. Pre-treatment of cells 
with 50 nM bafilomycin A1 completely blocked entry of both FECV-1683 and 
influenza virus, but only partially blocked entry by FIPV-1146 (approximately 40% 
inhibition). Sendai virus entry was unaffected by bafilomycin A1 at the concentrations 
tested. Treatment after entry with both NH4Cl and bafilomycin A1 had a minimal 
effect on FIPV-1146 and FECV-1683 at the concentrations shown in  Fig. 3,  however,    
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Figure 3.1 The effect of cysteine protease inhibitors on the growth of FIPV-1146 
and FECV-1683. A-72 cells were pre-treated with specified inhibitors at a 
concentration of 10 mM and then infected with virus. 3 h post-infection, fresh media 
without inhibitor was added to cells and 9 h post-infection media was collected. 
Production of extracellular virus from at least three independent experiments was 
determined by TCID50 assay. Error bars represent the standard deviation of the mean. 
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Figure 3.2 The effect of cathepsin L and cathepsin B inhibitors on the entry of 
FIPV-1146 and FECV-1683. A-72 cells were pre-treated with the cathepsin L 
inhibitor Z-FY-(t-Bu)-DMK (CatL-I) or the cathepsin B inhibitor CA074-Me (CatB-I) 
at the concentration specified, and then infected with virus. 6 h post-infection cells 
were fixed and stained for immunofluorescence microscopy with the anti-FCoV 
nucleocapsid mAb 17B7.1 (A). Images from at least three independent experiments 
were processed and quantified (B). To control for non-specific effects on replication, 
cells were also treated with inhibitors 1 h post-infection. For quantification, >1000 
cells were scored from three independent replicates of each experimental condition. 
Error bars represent the standard deviation of the mean. 
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Figure 3.2 (continued) 
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higher concentrations (>100 nM bafilomycin A1 and >30 mM NH4Cl) were able to 
significantly reduce infectivity of both viruses. Post-treatment with bafilomycin had 
no effect on influenza or Sendai virus infection at the concentrations shown in figure 
3.3. Overall these data show that FECV-1683 entry is highly dependent on low 
endosomal pH, whereas FIPV-1146 is much less dependent on low pH during entry. 
To determine whether the effects of low pH and cathepsin inhibitors were 
more generally applicable to serotype II coronavirus infections, we repeated key 
experiments using an additional feline coronavirus strain (FIPV-DF2), and also tested 
a variety of established feline cell lines (CRFK, AK-D and Fc2Lu). As shown in 
figure 3.4, the results were consistent with our previous data (see figures 3.1 and 3.2). 
The cathepsin B inhibitor CA074-Me almost completely prevented infection of all the 
feline coronaviruses tested, whereas the cathepsin L inhibitor Z-FY-(t-Bu)-DMK, 
selectively inhibited FECV-1683, but showed little or no effect on infection by FIPV-
1146 or FIPV-DF2. Likewise, the weak base NH4Cl selectively inhibited FECV-1683 
in all the cell lines tested, but showed only a marginal effect on the FIPV biotypes. 
To investigate whether the effect of cathepsins B and L occurred at the level of 
spike protein cleavage, concentrated FIPV-1146 and FECV-1683 viral particles were 
incubated with purified, activated cathepsin B and cathepsin L for 1 h at 37ºC, and 
then analyzed by Western blot with the anti-FCoV monoclonal antibody 22G6.4, 
specific for the S protein. As shown in figure 3.5, cathepsin L was unable to cleave the 
spike protein of FIPV-1146 under the conditions tested, but was clearly able to cleave 
the FECV-1683 spike protein, with an obvious cleavage product of approximately 
150–160 kDa. In contrast, cathepsin B was able to cleave both FIPV-1146 and FECV-
1683 spike proteins, also producing a cleavage product of approximately 150–160 kDa 
(Figure 3.5). The samples shown in figure 3.5 were treated with the endoglycosidase 
PNGase F, which resulted in a clearer representation of the cleaved product by 
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Western blot, compared to samples without PNGaseF pre-treatment, most likely due to 
heterogenous glycosylation of the spike protein in samples without the glycosidase. 
Overall, these data indicate that cathepsin L selectively cleaves the S protein of 
FECV-1683, whereas cathepsin B can cleave the S protein of both FECV-1683 and 
FIPV-1146. 
The in vivo targets of the highly virulent coronaviruses FIPV-1146 and FIPV-
DF2 include feline monocytes and macrophages. In order to assess whether cathepsins 
B and L might play a role in the entry of FIPV-1146 and FIPV-DF2 into its in vivo 
target, we isolated CD172a-positive, primary feline blood monocytes, pre-treated the 
cells with the cathepsin B inhibitor CA074-Me, or the cathepsin L inhibitor Z-FY-(t-
Bu)-DMK, and then infected them with FIPV-1146 or FIPV-DF2. As shown in figure 
3.6, the cathepsin B inhibitor significantly reduced infection by FIPV-1146 and FIPV-
DF2 (approximately 85–95% inhibition), however, the block was not as complete as 
observed in cell lines (see figures 3.2 and 3.4). In line with our data using cell lines, 
the cathepsin L inhibitor showed no significant effect on FIPV infection of primary 
feline monocytes. As expected (12), primary feline blood monocytes were only 
negligibly susceptible to infection with FECV-1683, hence a role for cathepsin B or L 
cannot be determined in this case (Figure 3.6). These data indicate that cathepsin B-
mediated cleavage of FIPV-1146 and FIPV-DF2 may play an important role in cells 
infected in vivo during the course of FIP. 
We show here the effects of low pH and cathepsin cleavage of the serotype II 
feline coronavirus spike protein, with a differential effect of low pH, and cathepsin B 
versus cathepsin L cleavage for the FECV and FIPV biotypes. The two biotypes are 
genotypically very similar and the strains FECV-1683 and FIPV-1146, in particular, 
are known to share a high degree of amino acid identity in their spike protein (>95%) 
yet cause radically different clinical outcomes—lethal vasculitis for FIPV-1146, 
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compared to mild enteritis for FECV-1683 (23).  Previous studies have shown that the 
S2 domain of the viral spike protein is a critical discriminating factor in FECV-1683 
and FIPV-1146 pathogenesis (46). The studies presented here raise the possibility that 
differential proteolysis of the spike (S2) protein might be an important factor in 
explaining the different pathogenic properties of these viruses. 
At present, we cannot definitely determine the exact point in the FCoV 
infectious cycle that cathepsin cleavage would occur. However, the in vivo 
localization of cathepsins to the endosome/lysosome system, together with absence of 
any obvious cleaved product in purified extracellular FCoV particles unless exogenous 
activated cathepsin is added, would strongly suggest that cleavage occurs in the 
endosome during virus entry. In support of this, we find that addition of cathepsin 
inhibitors after virus entry has occurred has no detectable effect on viral replication. 
While the use of feline aminopeptidase N (fAPN) as a receptor for serotype II feline 
coronaviruses is well established (51, 53, 54), many other aspects of the entry pathway 
have not been explored in great detail for these viruses. Based on the effects of 
lysosomotropic agents shown here, we suggest that all serotype II feline coronaviruses 
enter the endocytic pathway for virus entry, where they are primed for fusion 
activation by cathepsin cleavage, but that FECV-1683 is much more dependent on 
endosomal function, suggesting that FIPV-1146 and FIPV-DF2 may escape into the 
cytosol earlier in the endocytic pathway. Possibilities that might account for this are 
the differential cleavage of the FIPV spike protein by cathepsin L, or alternatively a 
lower threshold for any necessary low pH-dependent conformational changes for 
FIPV spike. It remains to be determined whether a similar situation with cathepsin 
cleavage exists for the serotype I FCoVs, which are not considered to share the same 
receptor as FECV-1683 and FIPV-1146 (14).  In general, the cleavage site of 
cathepsins is difficult to predict based on sequence specificity, and so we cannot at 
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present determine specifically where in the spike protein cathepsin B or L might 
cleave. However, based on the single 150–160 kDa cleaved product seen in Fig. 5 for 
both cathepsin B and L, it does appear that the spike protein is subject to single, 
distinct cleavage event for both proteases, most likely occurring at the same 
approximate position in S. We used the monoclonal antibody 22G6.4 to show this 
specific cleavage event, and while the epitope recognized by 22G6.4 is not known, by 
analogy to the many other S specific FCoV monoclonal antibodies that have epitopes 
in S1 (10, 38), we tentatively suggest that the 22G6.4-reactive epitope is also most 
likely to be within the S1 domain.  Based on the cleavage pattern shown in figure 3.5 
it does not appear that cleavage occurs at the S1/S2 boundary, but rather, the 150–160 
kDa cleavage products observed may represent cleavage within the C-terminal part of 
S2. As the C-terminal part of FCoV S2 has been previously considered to specify the 
pathogenic properties of FIPV (46), it will be interesting to determine if any of the 
specific mutations in the FIPV-1146 spike can account for the differential cathepsin-
sensitivity observed here. Interestingly, treatment with cathepsins L or B resulted in 
only a fraction of the spike protein being cleaved (approximately 17–34% cleaved 
depending on the cathepsin/virus combination; see figure 3.5 B). This may indicate 
that  the cleavage site  is  relatively inaccessible,   and  that  only  a  small  number  of 
spike proteins are cleaved during virus entry. In this regard, it is noteworthy that in 
many cases cleavage activation of a viral fusion protein does not necessarily occur on 
all copies of the protein (34). Our data also indicate that for FECV-1683 (which is 
cleaved by both cathepsin B and L), cleavage occurs to a greater degree than with 
cathepsin B (Figure 3.5). These data are consistent with inhibitor treatments where 
cathepsin B inhibitor had a greater effect on virus infection than cathepsin L inhibitor.  
Thus we consider that cathepsin B may be the more important protease mediating 
FCoV  entry,  with  cathepsin  L  possibly  having  a  more  secondary  role.   Cysteine  
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Figure 3.3 The effect of lysosomotropic agents on the entry of FIPV-1146 and 
FECV 1683. A-72 cells were pre-treated with NH4Cl or bafilomycin A at the 
specified concentration and then infected with virus. 6 h post-infection cells were 
fixed and stained for immunofluorescence microscopy with the anti-FCoV 
nucleocapsid mAb 17B7.1 (A). Images from at least three independent experiments 
were processed and quantified (B). To control for non-specific effects on replication, 
cells were also treated with lysomotrophic agents 1 h post-infection. For 
quantification, >1000 cells were scored from three independent replicates of each 
experimental condition. Error bars represent the standard deviation of the mean.  
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Figure 3.3 (continued) 
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Figure 3.4 The effects of cathepsin L and cathepsin B inhibitors, and low pH, on 
the infection of feline cells by serotype II FCoVs. CRFK, AK-D or Fc2Lu cells were 
pre-treated with either 10 mM cathepsin B inhibitor CA074-Me (CatB-I), 10 mM 
cathepsin L inhibitor Z-FY-(t-Bu)-DMK (CatL-I), or 10 mM NH4Cl, and then infected 
with virus. 6 h post-infection cells were fixed and stained for immunofluorescence 
microscopy with the anti-FCoV nucleocapsid mAb 17B7.1. Images from at least three 
independent experiments were processed and quantified. For quantification >500 cells 
were scored from three independent replicates. Error bars represent the standard 
deviation of the mean. 
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Figure 3.4 (continued) 
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Figure 3.5 Cleavage of FIPV-1146 and FECV-1683 by purified cathepsins. 
Concentrated virus preparations were incubated with purified cathepsin B, cathepsin 
L, or buffer alone for 1 h at 37ºC, followed by treatment with PNGase F. (A) Samples 
were then analyzed by western blot with the anti-FCoV spike mAb 22G6.4. (B) 
Quantification of western blot to show degree of cleavage. (CatL-I), or 10 mM NH4Cl, 
and then infected with virus. 6 h post-infection cells were fixed and stained for 
immunofluorescence microscopy with the anti-FCoV nucleocapsid mAb 17B7.1. 
Images from at least three independent experiments were processed and quantified. 
For quantification >500 cells were scored from three independent replicates. Error 
bars represent the standard deviation of the mean. 
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Figure 3.6 The effect of cathepsin inhibitors on the infection of primary feline 
blood monocytes.  Monocytes were purified from the blood of SPF cats, pre-treated 
with the cathepsin B inhibitor CA074-Me (CatB-I) or the cathepsin L inhibitor Z-FY-
(t-Bu)-DMK (CatL-I) at a concentration 10 mM, and infected with virus. 12 h post-
infection, cells were fixed and stained for immunofluorescence microscopy with the 
anti-FCoV nucleocapsid mAb 17B7.1 (A). Images from at least three independent 
experiments were processed and quantified (B). For quantification, >200 cells were 
scored from three independent replicates of each experimental condition. Error bars 
represent the standard deviation of the mean. 
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Figure 3.6 (continued) 
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proteases such as cathepsins B, L, K and S, are emerging as therapeutic targets for a 
range of diseases, including cancer, osteoarthritis and autoimmune disorders, with 
some candidate drugs currently in clinical trials (52, 55). Cathepsin inhibitors also 
show promise as drugs targeting virus entry (55). Our results show a clear role for 
cathepsin B during entry of serotype II feline coronaviruses, raising the possibility that 
cathepsin B inhibitors may be effective therapeutics to treat this incurable and lethal 
affliction of cats. 
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CHAPTER FOUR 
 
ACTIVATION OF P38 MAPK BY FELINE INFECTIOUS PERITONITIS 
VIRUS REGULATES PRO-INFLAMMATORY CYTOKINE PRODUCTION 
IN PRIMARY BLOOD DERIVED MONONUCLEAR CELLS* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* A.D. Regan, R.D. Cohen, G.R. Whittaker. 2009. Activation of p38 MAPK by feline 
infectious peritonitis virus regulates pro-inflammatory cytokine production in primary 
blood derived feline mononuclear cells. Virology. 384(1): 135-43. 
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4.1.  Summary 
Feline infectious peritonitis (FIP) is an invariably fatal disease of cats caused 
by systemic infection with a feline coronavirus (FCoV) termed feline infectious 
peritonitis virus (FIPV). The lethal pathology associated with FIP (granulomatous 
inflammation and T-cell lymphopenia) is thought to be mediated by aberrant 
modulation of the immune system due to infection of cells such as monocytes and 
macrophages. Overproduction of pro-inflammatory cytokines occurs in cats with FIP, 
and has been suggested to play a significant role in the disease process. However, the 
mechanism underlying this process remains unknown.  Here we show that infection of 
primary blood-derived feline mononuclear cells by FIPV WSU 79-1146 and FIPV-
DF2 leads to rapid activation of the p38 MAPK pathway and that this activation 
regulates production of the pro-inflammatory cytokine tumor necrosis factor alpha 
(TNF-alpha) and interleukin-1 beta (IL-1 beta).  FIPV-induced p38 MAPK activation 
and pro-inflammatory cytokine production was inhibited by the pyridinyl imidazole 
inhibitors SB 203580 and SC 409 in a dose-dependent manner. FIPV-induced p38 
MAPK activation was observed in primary feline blood-derived mononuclear cells 
individually purified from multiple SPF cats, as was the inhibition of TNF-alpha 
production by pyridinyl imidazole inhibitors. 
 
4.2.  Introduction 
Coronaviruses are a diverse family of enveloped positive-stranded RNA 
viruses that infect a wide range of species including humans.  Coronaviruses are 
divided into three groups in which group 1 and 2 infect mammals and group 3 infects 
birds (37). Feline coronaviruses (FCoVs) belongs to group 1 and are classified as 
either serotype I or II depending on the sequence of their spike (S) protein (40). In 
addition, each serotype is divided into two biotypes designated as either feline enteric 
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coronavirus (FECV) or feline infectious peritonitis virus (FIPV) based on their 
pathological outcome in cats (47). FECV is ubiquitous amongst felines and causes 
mild to often unapparent enteritis, while FIPV leads to a lethal systemic infection 
marked by severe granulomatous inflammation (35, 36, 50). The mechanism 
underlying this drastic difference in disease between the two biotypes remains elusive, 
namely because FECV and FIPV isolates from the same serotype are virtually 
indistinguishable on the genetic and antigenic level. However it has been shown that 
the two biotypes possess markedly different abilities to infect cells of the immune 
system, with FIPV isolates possessing an extended tropism that allows for the 
infection of macrophages and monocytes (43). Recent studies have suggested that this 
alteration in tropism may be due to mutations in the S protein that affect protein 
cleavage and fusion activation during entry (39, 41). 
Viral pathogens that infect immune cells (e.g. human immunodeficiency virus 
(HIV) and Dengue Virus) are known to induce aberrant cytokine production, a process 
which is proposed to play a role in the pathological outcome of their respective 
diseases (10, 20, 26). Studies of cats with FIP have shown that cytokine expressions 
are altered as compared to healthy animals (7, 21).  Specifically it has been noted that 
expression of the pro-inflammatory cytokine tumor necrosis factor alpha (TNF-alpha), 
interleukin-1 beta (IL-1 beta) and interleukin-6 (IL-6) are significantly increased in 
cats with FIP, and are likely produced by infected macrophages and monocytes (21, 
45, 46). It has been shown that TNF-alpha is able to induce feline T-cell apoptosis, 
making it the most likely causative agent of T-cell lymphopenia in FIPV-infected cats 
(7, 46). In addition TNF-alpha has been shown to increase expression of the FCoV 
receptor aminopeptidase N (APN) causing target cells to be more susceptible to viral 
infection and further exacerbate the disease (46). However despite their critical role in 
the pathological outcome of FIP, the mechanism regulating FIPV-induced 
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upregulation of pro-inflammatory cytokines remains undescribed. Mitogen-activated 
protein kinases (MAPKs) are a family of proteins that serve as components of 
signaling pathways within cells in order to process and respond to extracellular stimuli 
(38).  Typically, receptors on the cell surface initiate signaling cascades, which lead to 
phosphorylation and translocation of MAPKs to the nucleus where they regulate 
transcriptional activators (51). In recent years, it has become clear that MAPKs also 
regulate processes outside of the nucleus such as mRNA translation and cytoskeletal 
remodeling (12, 19). Three major MAPK pathways have been identified which are 
conserved in all eukaryotic cells ranging from yeast to mammals. These pathways are 
designated as Extracellular Signal-Regulated Kinases 1 and 2 (ERK1/2), c-Jun N-
terminal Kinases (JNK1) and p38 MAPK (34).  In general the ERK pathway is 
activated by proliferative stimuli, while the JNK and p38 MAPK pathways are 
activated by extracellular stresses such as ultraviolet light, heat and osmotic shock 
(34). p38 MAPK was originally identified as the target of pyridinyl imidazole 
compounds that were shown to inhibit the production of IL-1 and TNF-alpha in 
lipopolysaccharide (LPS)-stimulated human monocytes (23). Subsequent studies have 
shown that the p38 MAPK pathway is responsible for the phosphorylation of a large 
group of transcriptional and translational response elements which directly regulate 
the expression of a wide variety of pro-inflammatory cytokines (22).  Due to its 
involvement in cytokine regulation, we reasoned that the p38 MAPK pathway might 
play a role in the increased production of pro-inflammatory cytokines observed in cats 
with FIP. In this study we examined the activation of the p38 MAPK pathway in 
response to infection by FIPV in primary feline blood-derived mononuclear cells.  We 
also investigated the role of p38 MAPK in TNF-alpha, IL-1 beta and IL-6 production, 
and the effect of p38 MAPK inhibitors on these processes. 
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4.3. Materials and methods 
Primary feline blood-derived mononuclear (PFBM) cells were individually 
purified from four male SPF cats (animal ID# 07PJO7, 07PGP2, 07PGV4, 07PGV5) 
and three female SPF cats (animal ID# 07FGR2, 07FGV6, 07FJM5) (Liberty 
Research, Waverly, NY) using a standard Ficoll-paque gradient (GE Healthcare) as 
specified by the manufacturer. Cells were seeded in 24-well plates with tissue culture 
treated glass coverslips and allowed to attach overnight. After washing, cells were 
incubated in the presence of 5% CO2 at 37 °C in RPMI-1640 media pH7.4 
supplemented with 10% Fetal Bovine Serum (FBS), 2 mM glutamine, 100 U/ml 
penicillin and 10 μg/ml streptomycin.  The purity of PFBM preparations were 
routinely checked by immunofluorescence microscopy using the marker DH59B 
(Veterinary Medical Research & Development Inc., Pullman, WA). Crandell-Reese 
Feline Kidney cells were obtained from the American Type Culture Collection 
(ATCC) and cultured and maintained according to ATCC guidelines. 
FIPV WSU 79-1146 (FIPV-1146) was obtained from the ATCC. FIPVDF2 
was provided by Dr. Ed Dubovi (Animal Health Diagnostic Center, New York State 
College of Veterinary Medicine, Cornell University).  Both viruses were grown by 
inoculating CRFK cells at a MOI of 0.01 and collecting supernatant after CPE was 
observed in 80% of cells which typically occurred between 48 and 72 h. Supernatant 
was clarified by a low speed centrifugation step (1250 X g for 10 min) and viral 
particles were then pelleted by centrifugation at 28,000 rpm in a SW28 rotor (Sorvall) 
for 60 min. Pellets were resuspended in phosphate-buffered saline (PBS). Virus titers 
were determined by plaque assays on CRFK cells using standard techniques. For UV 
inactivation, a thin layer of viral suspension was exposed to UV light (30 W) at a 
distance of 10 cm for 5 min. Inactivation was verified by performing infection assays 
in CRFK and PFBM cells as described. 
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The anti-phospho-p38 MAPK (Thr180/Tyr182) (3D7) rabbit monoclonal 
antibody (mAb) was obtained from Cell Signaling Technologies (Danvers, MA). The 
anti-p38 MAPK (N-20) goat polyclonal antibody (pAb) and anti-TNF-alpha (N-19) 
goat pAb were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The anti-
FIPV nucleocapsid (N) protein mAb (17B7.1) was provided by Dr. Ed Dubovi 
(Animal Health Diagnostic Center, New York State College of Veterinary Medicine, 
Cornell University). Anti-CD127a mAb DH59B was obtained from Veterinary 
Medical Research and Development, Inc. (Pullman, WA). The feline TNF-alpha 
ELISA kit (TNF-alpha/TNFSF1A), feline IL-1 beta ELISA kit (IL-1 beta/IL-1F2), 
feline IL-6 ELISA kit, and associated antibodies and detection reagents were obtained 
from R&D Systems (Minneapolis, MN). The p38 MAPK inhibitors 4-(4-
Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole (SB 203580) 
and 4-(3-(4-Chlorophenyl)-5-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl) pyrimidine 
(SC 409) were obtained from Calbiochem (San Diego, CA).  PFBM cells were 
incubated in low-serum media (1% FBS) for 12 h before inoculation with the specified 
virus at an MOI of 100, or pretreatment with the specified inhibitor for 2 h followed 
by infection. For p38 MAPK activation experiments, cells were lysed at the specified 
time-points in lysis buffer (1% Triton X-100, 50 mM Tris–HCl, 150 mM NaCl, 1 mM 
EDTA, 1 mM DTT, 50 mM beta-glycerophosphate, 100 mM sodium vanadate, pH 
7.4) supplemented with 1x complete protease inhibitor cocktail (Roche). Lysates were 
clarified by centrifugation at 13,000 rpm in a table-top centrifuge at 4°C for 15 min 
before freezing at −80°C for later analysis. For immunofluorescence assays, cells were 
fixed at the specified time-points with 3% paraformaldehyde. For analysis of cytokine 
production, supernatant was collected 24 h post-innoculation (p.i.) before freezing at 
−80°C for later analysis.  Fixed cells were labeled with the specified antibodies as 
described previously (6). Cells were viewed on a Nikon Eclipse E600 fluorescence 
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microscope, and images were captured with a Sensicam EM camera and analyzed with 
IPLab software.   
SDS sample buffer was added to lysates and the reaction was heated at 95°C 
for 10 min before separation using a 4–20% SDS-PAGE gel at 200 V for 2 h. Gels 
were electroblotted to PVDF membrane at 200 A for 2 h, blocked with 5% bovine 
serum albumin and probed with the specified antibody at 4°C for 12 h. Membranes 
were developed using either anti-rabbit antibody (Southern Biotech, Birmingham AL) 
or anti-goat antibody (Santa Cruz Biotechnology, Santa Cruz CA) linked to 
horseradish peroxidase and ECL substrate (Pierce, Rockford IL) and images captured 
using a Fujifilm LAS-3000 CCD camera. For western blot analysis of TNF-alpha 
production, supernatants were concentrated 50× using iCon 9 kDa molecular weight 
cut-off spin columns (Pierce, Rockford IL) and analyzed by western blot as described 
above. Western blot densitometry analysis of signal intensity was performed using 
ImageJ software. For quantification of cytokine production, supernatants were 
processed with the specified ELISA kits (R&D Systems) using standard capture 
ELISA techniques as specified by the manufacturer. 
 
4.4. Results and Discussion 
The p38 MAPK pathway has been shown to be activated by multiple viral 
pathogens during infection (1, 2, 8, 9, 16, 53). To determine whether the p38 MAPK 
pathway is activated during the infectious lifecycle of FIPV, primary feline blood-
derived mononuclear (PFBM) cells were inoculated with either FIPV-1146 or FIPV-
DF2 at an MOI of 100. Untreated cells and infected cells ranging from 15 min to 12 h 
p.i. were lysed and analyzed by western blot with the anti-phospho-p38 MAPK mAb 
(3D7). Untreated cells showed a minimal level of p38 MAPK phosphorylation, 
however addition of either virus isolate caused rapid phosphorylation of p38 MAPK 
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(~600% increase) within 15 min p.i. (Figures 4.1 A and C).  p38 MAPK underwent 
de-phosphorylation by 60 min and then showed a second phase of phosphorylation 
later in infection between 6 and 12 h p.i., which was less pronounced (Figure 4.1 A). 
To determine whether viral replication was required for FIPV-induced p38 MAPK 
activation, UV-inactivated virus was added to PFBM cells and analyzed by western 
blot as described above (Figure 4.1 B). UV-treated FIPV also induced p38 MAPK 
phosphorylation, however the activation was not biphasic, and instead remain 
sustained throughout the 12 h time-course (Figure 4.1 B).  Membranes were re-probed 
with anti-p38 MAPK (N-20) pAb to show that an equal amount of p38 MAPK was 
present in each sample (Figures 4.1 A and B). To further confirm that the p38 MAPK 
pathway is activated by FIPV, PFBM cells were inoculated with FIPV-1146 at an 
MOI of 100 before fixing the cells for immunofluorescent microscopy. p38 MAPK 
again showed a rapid phosphorylation by 15 min p.i. while the total amount of p38 
MAPK remained unchanged (Figure 4.2). In addition the p38 MAPK in infected cells 
showed increased nuclear localization as compared to untreated cells, a phenomenon 
highly associated with the regulation of transcriptional activators (Figure 4.2). These 
data indicate that the p38 MAPK pathway is activated during infection of PFBM cells 
by FIPV, and that viral replication is dispensable for this activation to occur. 
The p38 MAPK pathway was first discovered by investigating the target of 
pyridinyl imidazole compounds which blocked LPS-induced cytokine induction in 
human monocytes (23). To test the effect of pyridinyl imidazole inhibitors on FIPV-
induced p38 MAPK phosphorylation, PFBM cells were treated with 10 μM of either 
SB 203580 or SC 409 (or 0.1% DMSO as a control) for 2 h before inoculating with 
FIPV-1146 or FIPV-DF2 at an MOI of 100. 15 min p.i. cells were lysed and analyzed 
by western blot with the anti-phosphop38 MAPK mAb (3D7). Cells which were 
pretreated with DMSO alone showed rapid FIPV-induced phosphorylation of p38 
83 
 
MAPK, however those which were pretreated with either SB 203580 or SC 409 
showed no activation as compared to uninfected cells (Figure 4.3). These data 
demonstrate that FIPV-induced p38 MAPK activation is blocked by pyridinyl 
imidazole inhibitors.   
Activation of the p38MAPKpathway has been shown to be required for replication of 
some viruses including the murine coronavirus Mouse Hepatitis Virus (MHV) (2). To 
investigate whether activation of the p38 MAPK pathway is required for replication of 
FIPV, PFBM cells were treated with 10 μM of either SB 203580 or SC 409 (or 0.1% 
DMSO as a control) for 2 h before inoculating with FIPV-1146 or FIPV-DF2. 12 h p.i. 
cells were fixed and stained for with the anti-FIPV N protein mAb (17B7.1). As 
shown in figure 4.4, pretreatment with p38 MAPK inhibitors has no significant effect 
on FIPV replication in PFBM cells. Activation of p38 MAPK by viral pathogens has 
been shown to induce the production of pro-inflammatory cytokines such as TNF-
alpha, IL-1 beta and IL-6 (2, 13, 24, 25; 42, 48, 52). To investigate whether TNF-
alpha production in FIPV-infected PFBM cells is regulated by p38 MAPK activation,  
PFBM cells were treated with 10 μM of either SB 203580, SC 409 or 0.1% DMSO for 
2 h before  inoculating  with  FIPV-1146 or  FIPV-DF2  at  an  MOI  of  100.    
24 h p.i. supernatants were collected, concentrated and analyzed by western 
blot with the anti-TNF-alpha (N-19) pAb. Cells which were pretreated with DMSO 
alone showed significant production of TNF-alpha, however those which were 
pretreated with either SB 203580 or SC 409 showed no detectable production of TNF-
alpha as compared to uninfected cells (Figure 4.5 A). To quantify the production of 
TNF-alpha, infections were performed as described above, except at 24 h p.i. 
supernatants were collected and analyzed by anti-TNF-alpha capture ELISA. Infected 
cells which were pretreated with DMSO alone showed significant production of TNF-
alpha (N750 pg/ml)  however pretreatment with 10 μM SB 203580 and 10 μM SC 409  
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Figure 4.1 FIPV induces phosphorylation of p38 MAPK in PFBM cells. PFBM 
cells were infected with either untreated FIPV-1146 or FIPV-DF2 viral particles (A), 
or UV inactivated particles (B), at an MOI of 100. Cells were lysed at the specified 
times p.i. and analyzed by western blot with the anti-phospho-p38 MAPK mAb (3D7) 
and re-probed with anti-p38 MAPK (N-20) pAb. Signal intensity from two time-
course infections of untreated FIPV-1146 and one time-course infection of untreated 
FIPV-DF2 were quantified by densitometry analysis with Image J software (C). 
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Figure 4.1 (continued) 
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Figure 4.2 Immunofluorescence of FIPV-induced p38 MAPK activation and 
nuclear re-localization. PFBM cells were infected with FIPV-1146 at an MOI of 100. 
Cells were fixed at 15 min p.i. and stained with the anti-phospho-p38 MAPK mAb 
(3D7), the anti-p38 MAPK (N-20) pAb and Hoechst. 
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Figure 4.3 Inhibition of FIPV-induced p38 MAPK activation in PFBM cells by 
the pyridinyl imidazole compounds SB 203580 and SC 409.  PFBM cells were 
pretreated with 10 μM of either SB 203580 or SC 409 (or 0.1% DMSO as a control) 
for 2 h before inoculating with FIPV-1146 or FIPV-DF2 at an MOI of 100. 15 min p.i. 
cells were lysed and analyzed by western blot with the anti-phospho-p38 MAPK mAb 
(3D7) and re-probed with anti-p38 MAPK (N-20) pAb. 
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Figure 4.4 Inhibition of the p38 MAPK pathway does not significantly affect 
FIPV infection of PFBM cells. PFBM cells were pretreated with 10 μM of either SB 
203580 or SC 409 (or 0.1% DMSO as a control) for 2 h before inoculating with FIPV-
1146 or FIPV-DF2. Cells were fixed 12 h p.i. and stained with the anti-FIPV-N 
protein mAb (17B7.1) (A). For quantification, N500 cells were scored from three 
independent replicates of each experimental condition (B). Error bars represent the 
standard deviation of the mean. 
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Figure 4.4 (continued) 
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Figure 4.5 FIPV-induced TNF-alpha production by PFBM cells is regulated by 
p38 MAPK activation. PFBM cells were pretreated with 10 μM of either SB 203580 
or SC 409 (or 0.1% DMSO as a control) for 2 h before inoculating with FIPV-1146 or 
FIPV-DF2 at an MOI of 100. 24 h p.i. supernatants were collected, concentrated and 
analyzed by western blot with the anti-TNF-alpha (N-19) pAb (A). 24 h p.i. 
supernatants were collected and TNF-alpha production was quantified by anti-TNF-
alpha capture ELISA (B). TNF-alpha produced from untreated cells was below the 
detection limit of the assay (10 pg/ml). 
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 Figure 4.5 (continued) 
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Figure 4.6 FIPV-induced TNF-alpha production is inhibited in a dose-dependent 
manner by SB 203580 and SC 409. PFBM cells were pretreated with either SB 
203580 or SC 409 at a range of concentrations (10 μM, 1 μM or 0.1 μM) or 0.1% 
DMSO for 2 h before inoculating with FIPV-1146 at an MOI of 100. 24 h p.i. 
supernatants were collected and TNF-alpha production was quantified by anti-TNF-
alpha capture ELISA. TNF-alpha from untreated cells was below the detection limit of 
the assay (10 pg/ml). 
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resulted in a 8-fold and 4-fold reduction in TNF-alpha production respectively (Figure 
4.5 B). Uninfected cells produced no TNF-alpha, or were below the detection level of 
the assay. Overall these data indicate that production of the pro-inflammatory cytokine 
TNF-alpha in FIPV infected PFBM cells is regulated by activation of the p38 MAPK 
pathway. 
To show that the reduction of FIPV-induced TNF-alpha production by SB 
203580 and SC 409 was specific to the pyridinyl imidazole inhibitors, PFBM cells 
were treated with either SB 203580 or SC 409 at a range of concentrations (10 μM, 1 
μM or 0.1 μM) or 0.1% DMSO for 2 h before inoculating with FIPV-1146 or FIPV-
DF2 at an MOI of 100. As seen in our previous data, PFBM cells which were 
pretreated with DMSO alone produced significant amounts of TNF-alpha however 
pretreatment with SB 203580 and SC 409 resulted in a significant reduction in TNF-
alpha production in a dose-dependent manner (Figure 4.6). 
It is known that individual animals can vary in their reaction to infection by 
FIPV (21). To determine whether or not FIPV-induced p38 MAPK activation was 
specific to a single animal, PFBM cells were individually prepared from six additional 
SPF cats (07PGP2, 07PGV4, 07PGV5, 07FGR2, 07FGV6, 07FJM5). PFBM cells 
individually purified from each animal were inoculated with FIPV-1146 at an MOI of 
100. Untreated cells and infected cells (15 min p.i.) were lysed and analyzed by 
western blot with the anti-phospho-p38 MAPK mAb (3D7). Consistent with our 
previous data, untreated cells showed a minimal level of p38 MAPK phosphorylation 
while addition of FIPV caused a rapid phosphorylation of p38 MAPK in PFBM cells 
from all six cats (Figure 4.7). Membranes were re-probed with anti-p38 MAPK (N-20) 
pAb to show that an equal amount of p38 MAPK was present in each sample (Figure 
4.7). In addition, the regulation of TNF-alpha production by p38 MAPK was analyzed 
in PFBM cells from all six SPF cats. PFBM cells from each animal were treated with 
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10 μM SC 409 or 0.1% DMSO for 2 h before inoculating with FIPV-1146 at an MOI 
of 100. 24 h p.i. supernatants were collected and analyzed by anti-TNF-alpha capture 
ELISA. While the baseline level of TNF-alpha production differed slightly amongst 
all of the cats tested, treatment with the p38 inhibitor SC 409 resulted in the same 
trend observed in our previous experiments: a significant reduction in TNF-alpha 
levels (between 3-fold to 8-fold) (Figure 4.8). These data taken together suggest that 
FIPV-induced activation of the p38 MAPK pathway in PFBM cells represents a 
common mechanism by which this virus promotes TNF-alpha production in cats.   
Cats with FIP have also been reported to show increased levels of the pro-
inflammatory cytokines IL-1 beta and IL-6. To investigate whether IL-1 beta and IL-6 
production in FIPV-infected PFBM cells is regulated by p38 MAPK activation, PFBM 
cells were treated with 10 μM of either SB 203580, SC 409 or 0.1% DMSO for 2 h 
before inoculating with FIPV-1146 at an MOI of 100. 24 h p.i. supernatants were 
collected and analyzed by anti-IL-1 beta and anti-IL-6 capture ELISA. Infected cells 
which were pretreated with DMSO alone showed significant production of IL-1 beta 
(~200 pg/ml) however pretreatment with 10 μM SB 203580 and 10 μM SC 409 
resulted in a 7-fold and 4-fold reduction in IL-1 beta production respectively (Figure 
4.9). Neither infected nor uninfected PFBM cells produced significant levels of IL-6 
(Figure 4.9). Overall, these data indicate that both TNF-alpha and IL-1 beta production 
in FIPV-infected PFBM cells is regulated by p38 MAPK activation, a situation that 
does not apply to IL-6. 
Modulation of signaling pathways by viruses is becoming recognized as a key 
pathogenic determinant in viral diseases mediated by aberrant host immunological 
responses. In the case of FIP, cytokine production is markedly altered between 
animals with disease as compared to healthy animals, with overproduction of the pro-
inflammatory cytokine TNF-alpha in particular being indicative of a poor outcome 
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(21). Feline TNF-alpha causes apoptosis in feline T-cells (implicating it as the 
causative agent of T-cell lymphopenia), and upregulates the FIPV receptor APN 
making target cells more susceptible to infection in vitro (7, 21, 45, 46). It has been 
shown previously that FIPV-infected monocytes upregulate the expression of TNF-
alpha, however the mechanism regulating this process remains undescribed. 
In this study we show that infection by FIPV causes a rapid activation of the 
p38 MAPK pathway in PFBM cells, and that this process directly regulates production 
of the pro-inflammatory cytokines TNF-alpha and IL-1 beta.  As shown in figure 4.1, 
FIPV-induced p38 MAPK activation in PFBM cells occurs in a biphasic temporal 
pattern which mimics that observed with other viral pathogens that activate MAPK 
pathways during infection such as influenza virus.  At present we are unable to define 
the mechanism by which FIPV particles are able to activate the p38 MAPK pathway, 
however the rapid nature of the initial activation suggests that it occurs early during 
entry; likely due to interactions between the S protein and its receptor. This model is 
further supported by the observation that UV-inactivated virus also induce rapid 
activation of the p38 MAPK pathway. This activation is markedly different than that 
reported in MHV infected cells, where activation did not occur until 6–12 h p.i., and 
UV-treated viral particles did not induce phosphorylation of p38 MAPK (2).  It is 
notable that the FIPV receptor APN localizes to lipid rafts (30, 32) which are known 
to be a signaling portal for the p38 MAPK pathway (4, 15, 33, 44, 49, 54).  In fact it 
has recently been shown that rhinovirus activates the p38 MAPK pathway through the 
actions of lipid rafts and RhoA (8). Further investigation will be necessary to 
determine the role of APN and lipid rafts in the initial phase of FIPV-induced p38 
MAPK activation and TNF-alpha/IL-1 beta production.  Interestingly, UV-inactivated 
FIPV induced prolonged p38 MAPK activation, rather than the biphasic activation 
induced by untreated viral particles. This suggests that FIPV may activate p38 MAPK 
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during entry, but then suppresses p38 MAPK during the early phase of replication. 
The second phase of FIPV-induced p38 MAPK activation induced by untreated viral 
particles (6 h p.i.) may be caused by the production of pro-inflammatory cytokines. It 
has been shown that TNF-alpha can itself activate the p38 MAPK through signaling 
associated with the cytoplasmic domain of its receptors TNF receptor 1 (TNFR1)-
associated death domain protein (TRADD) and TNF receptor-associated factor 2 
(TRAF2) (5, 17, 18). Therefore TNF-alpha produced during the initial phase of FIPV-
induced p38 MAPK activation, may  be  the  cause  of  the  latter  phase  of activation.  
Pretreatment with the pyridinyl imidazole inhibitors SB 203580 and SC 409 blocked 
production of TNF-alpha and IL-1 beta suggesting that p38 MAPK directly regulates 
production of the cytokines in FIPV-infected PFBM cells. The upregulation of IL-6 
production was  not observed in FIPV-infected  PFBM  cells,  suggesting  that another 
cell type may be responsible for its production in cats with FIP. At this time the 
mechanism by which p38 MAPK regulates pro-inflammatory cytokine production in 
FIPV-infected PFBM cells is unknown, however regulation of cytokines by MAPKs 
in analogous systems occurs by affecting either transcriptional regulation, translational 
regulation, or both (22). For example the recently emerged severe acute respiratory 
syndrome coronavirus (SARS-CoV) is also known to infiltrate immune cells such as 
monocytes and macrophages and activate the p38 MAPK pathway (3, 11, 14, 31). 
SARS-CoV infection causes a p38 MAPK-dependent phosphorylation of downstream 
transcriptional regulators such as activating transcription factor 1 (ATF-1) and signal 
transducer and activator of transcription 3 (STAT-3), as well as translational 
regulators such as MAPK activate protein kinase 2 (MAPKAPK2) and the eukaryotic 
initiation factor 4E (eIF4E) (27-29). As seen in figure 4.2 it appears that FIPV causes 
increased p38 MAPK nuclear localization suggesting that the activation of 
transcription  factors  likely play a role in pro-inflammatory production in PFBM cells,  
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Figure 4.7 FIPV-induced p38 MAPK activation in PFBM cells from six 
individual SPF cats. PFBM cells were individually prepared from three male 
(07PGP2, 07PGV4, 07PGV5) and three female (07FGR2, 07FGV6, 07FJM5) SPF 
cats. Cells from each animal were inoculated with FIPV-1146 at an MOI of 100.  15 
min p.i. cells were lysed and analyzed by western blot with the anti-phospho-p38 
MAPK mAb (3D7) and re-probed with anti-p38 MAPK (N-20) pAb. 
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Figure 4.8 FIPV-induced TNF-alpha production by PFBM cells from six SPF cats 
is inhibited by SC 409. PFBM cells were individually prepared from three male 
(07PGP2, 07PGV4, 07PGV5) and three female (07FGR2, 07FGV6, 07FJM5) SPF 
cats. Cells from each animal were inoculated with FIPV-1146 at an MOI of 100. 24 h 
p.i. supernatants were collected and TNF-alpha production was quantified by anti-
TNF-alpha capture ELISA. TNF-alpha from untreated cells was below the detection 
limit of the assay (10 pg/ml). 
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Figure 4.8. (continued) 
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Figure 4.9 Production of IL-l beta and IL-6 by FIPV-infected PFBM cells.  PFBM 
cells were pretreated with 10 μM of either SB 203580 or SC 409 (or 0.1% DMSO as a 
control) for 2 h before inoculating with FIPV-1146 at an MOI of 100. 24 h p.i. 
supernatants were collected and IL-1 beta and IL-6 production was quantified by anti 
IL-1 beta or anti-IL-6 capture ELISA.   
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 however this also does not exclude a role for translational regulation. Future studies 
examining the role of downstream transcriptional and translational regulators in FIPV-
infected PFBM cells should clarify the mechanism regulating this process. Another 
aspect complicating the treatment of FIP is the diverse reactions to infection displayed 
by cats with the disease (21). Our results suggest that activation of the p38 MAPK 
pathway and its regulation of TNF-alpha production is common to PFBM cells of all 
cats, however further sampling of animals throughout different geographic regions 
will be required to confirm this conclusion.  Pyridinyl imidazole compounds have 
been shown to be efficacious therapeutic agents for blocking the mediators of chronic 
inflammatory diseases such as rheumatoid arthritis (22). In fact, several p38 MAPK 
inhibitors have shown promise in animal models of inflammatory diseases and some 
have even reached human clinical trials (22). Our results show a clear activation of 
p38 MAPK by FIPV during infection, and that this activation is responsible for pro-
inflammatory cytokine production which is a key contributor to the pathological 
changes observed in cats with FIP. This raises this possibility that p38 MAPK 
inhibitors, alone or in conjunction with other therapies, may possess therapeutic 
benefits in the treatment of cats with FIP. 
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5.1 Conversion of FECV to FIPV 
 Feline enteric coronavirus (FECV) infection is ubiquitous in domestic and wild 
cats throughout the world (2).  Conversion of FECV to feline infectious peritonitis 
virus (FIPV) is the cause of feline infectious peritonitis (FIP), however the factors 
controlling this process are not understood (25).  The inability to distinguish between 
FECV and FIPV is a major reason why diagnosing FIP is extremely difficult.  
Currently FIP can be confirmed by positive anti-feline coronavirus immunofluorescent 
staining of primary monocytes (positive prediction value = 1.00), however false 
negatives are common with this method (negative prediction value = 0.57) (6).  Post-
mortem histopathological analysis can confirm cases of FIP with absolute certainty; 
however this is of little use to veterinarians attempting to treat their patient (6).  A 
simple PCR-based test which could identify the specific mutations responsible for 
conversion of FECV to FIPV would therefore be invaluable.   
Using reverse genetics and spike protein chimeras, mutations controlling the 
conversion of FECV to FIPV have previously been narrowed down to the S2 region of 
the spike protein for FCoV-2 (18).  The S2 region is responsible for facilitating 
membrane fusion, suggesting that an alteration in the fusogenic properties of the spike 
protein could be responsible for the switch.  Data in this thesis demonstrates a distinct 
difference in the requirement for cathepsin cleavage of the spike protein for FECV-
1683 and FIPV-1146.  FECV-1683 was shown to require cleavage by both cathepsin L 
(catL) and cathepsin B (catB).  FIPV-1146 also requires catB cleavage, but appears to 
have shed its reliance on catL cleavage.  This data was mirrored by the ability of both 
catL and catB to cleave within the S2 region of FECV-1683 spike, whereas only catB 
could cleave within the S2 region of the FIPV-1146 spike protein.  Also shown here is 
that FECV-1683 requires low pH for spike protein-mediated fusion to occur, while 
FIPV-1146 is apparently able to fuse at or near neutral pH.  It is possible that the 
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differential cleavage within the S2 region is responsible for altering the pH-dependent 
fusogenic properties of the spike protein, thereby fundamentally altering viral tropism.   
Within S2 there are only 14 amino acid substitutions between FECV-1683 and 
FIPV-1146.  Our data suggests that one or more mutations within a catL cleavage site 
might control the switch from FECV to FIPV.  CatL has been shown to preferentially 
cleave at sites with an arginine or lysine at P1, and a bulky hydrophobic residue at P2 
(i.e. phenylalanine, tryptophan, tyrosine), and no bulky hydrophobic residues at P3 or 
P4 (4).  An examination of the S2 region of the FECV-1683 spike protein uncovered 
eight potential catL sites.  Of these eight potential sites, only one is mutated in the S2 
region of FIPV-1146 (R961G) (Figure 5.1).  Interestingly this particular arginine is 
conserved amongst the spike protein of all reported coronavirus spike proteins (3).  
The arginine is directly adjacent of the putative coronavirus spike protein fusion 
peptide, and cleavage at this site has recently been shown to be required for the fusion 
of coronaviruses such as SARS-CoV and IBV (3, 12, 27).  Recent sequencing efforts 
in our laboratory have also uncovered another FIPV isolate with a mutation at this 
arginine, only the second such example ever to be reported in a coronavirus (11).   
If this conserved arginine is required for coronavirus spike protein-mediated 
fusion, how can it be mutated in viable FIPV isolates?  Data in this thesis also shows 
that catB is able to cleave in the S2 region of both the FECV-1683 and FIPV-1146 
spike proteins, at the same or a closely adjacent site.  It is therefore possible that while 
mutation of the conserved arginine in FIPV-1146 disrupts the catL site, the protein 
shifts its proteolytic activation solely to catB.  CatB also preferentially cleave at sites 
with an arginine or lysine at the P1 position, however it is unique among the cathepsin 
family proteases in that in can tolerate an arginine or lysine at the P2 position.  An 
examination of the S2 region of the FIPV-1146 spike protein reveals that a potential 
catB  cleavage site remains intact  site  just two amino acids upstream of the  disrupted  
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          930                              * # 
FECV-1683 TENLDPIYKEWPNIGGSWLGGLKDILPSHNSKRKYRSAIEDLLFDKAVTSGLGTVDEDY 
          ::::::::::::.:::::::::::::::::::::: ::::::::::.:::::::::::: 
FIPV-1146 TENLDPIYKEWPSIGGSWLGGLKDILPSHNSKRKYGSAIEDLLFDKVVTSGLGTVDEDY 
            930                            * 
 
 
Figure 5.1 Sequence alignment of potential cathepsin cleavage sites upstream of 
the fusion peptide in the FECV-1683 and FIPV-1146 spike proteins.  Potential 
cathepsin L cleavage sites (#) and cathepsin B cleavage sites (*) are denoted.  The 
putative fusion peptide is boxed.  The spike protein of FECV-1683 contains the 
conserved cleavage arginine at the P1 position of a potential cathepsin L site, directly 
upstream of the fusion peptide.  A mutation in the spike protein of FIPV-1146 
(R961G) disrupts the potential cathepsin L cleavage site, while maintaining a potential 
cathepsin B cleavage site.  In this model, two additional amino acids would be added 
to the N-terminus of the FIPV-1146 fusion peptide.   
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catL site (Figure 5.1).  It is possible that destruction of the catL site in the spike 
protein of in FIPV-1146 shifts cleavage upstream to the catB site.  If this occurred 
then the fusion peptide would be modified by the addition of two amino acids to the 
N-terminus (i.e. Y960, G961) (Figure 5.1). 
It is known that tyrosine and glycine residues are critical amino acids for the 
function of other viral fusion peptides (26).  In fact, recent studies in our laboratory 
using liposomal fusion assays have shown that the endogenous FECV fusion peptide 
requires low pH to mediate fusion; however addition of an YG motif to the N-
terminus facilitates efficient fusion at neutral pH (17).  Taken together this suggests a 
model in which FECV requires endocytosis and trafficking to late endosomes in order 
to contact cathepsin L and low pH, while FIPV is able to fuse at or near the cell 
surface (Figure 5.2).  This could explain how FIPV is able to infect immune cells such 
as macrophages, which rely upon the harsh environment of a lysosome to disable viral 
pathogens.   
To test this model it will be necessary to pinpoint the cathepsin cleavage sites 
in the FECV-1683 and FIPV-1146 spike proteins.  This may be accomplished 
purifying spike protein, cleaving with either catL or catB, and subjecting the 
fragments to N-terminal sequencing.  Purification of the spike protein may be 
accomplished by immunoprecipitation from viral particles using a monoclonal anti-
spike antibody, or by expressing and purifying recombinant protein.  If the latter 
method is employed, it will be necessary to remove the transmembrane and 
cytoplasmic domain in order to facilitate secretion of the protein.  This method will 
also require the addition of a trimerization sequence in order to achieve structural 
authenticity.   In  addition,  expression  in  either  insect  cells  (i.e. baculovirus,  or  S2  
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Figure 5.2  A model to explain the different tropisms of FECV and FIPV.   FECV 
binds its receptor Aminopeptidase N (APN) and is endocytosed into the cell.  The 
FECV spike protein requires cathepsin L, cathepsin B and low pH for fusion to occur.  
FIPV also bind APN, but is able to fuse at the surface due to its modified fusion 
peptide (A).  In a macrophage, this differential entry pathway allows FIPV to avoid 
destruction by lysosomes (B). 
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drosophila) or mammalian cells (i.e. 293T cell expression) will be necessary to ensure 
glycosylation and proper folding of the spike protein.   
The recent advent of a feline coronavirus reverse genetics system allows the 
production of viral particles with mutated spike proteins.  In will be interesting to test 
the phenotype of FECV-1683 viral particles expressing the aforementioned R961G 
mutation in the spike protein, as well as FIPV-1146 particles with the G961R 
reversion, in immune cells.  In addition particles with the corresponding spike 
mutation may be produced by the commonly employed retrovirus or VSV pseduovirus 
systems.  
 
5.2  Dendritic cells and pathogenesis 
FIPV is phenotypically distinguished by its ability to infect immune cells, 
traditionally assumed to be macrophages and monocytes in vivo (20).  In this thesis, it 
is shown that the lectin DC-SIGN is required for efficient cellular entry into immune 
cells. DC-SIGN is expressed on macrophages, but even more highly expressed on 
dendritic cells.  The role of dendritic cells in FIP has yet to be studied; however they 
remain a possible “ground zero” for the propagation of FIPV mutants.  Dendritic cells 
are produced in a so-called “immature” form in which they sample their extracellular 
environment by endocytosis (23).  If they contact and recognize a threat (e.g. bacterial 
lipopolysaccharide, viral antigen, etc.) they become activated, or “mature” dendritic 
cells.  Unlike macrophages, activated dendritic cells migrate from their respective 
tissue to the lymph nodes in order to elicit an immune response (8).  This is significant 
since the lymph nodes have been implicated as an epicenter of FIPV infection in vivo 
(16).  It is therefore possible that dendritic cells which become infected by FIPV in the 
gut, then migrate to the lymph node thereby spreading the virus systemically.  
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The majority of data in this thesis was generated using human DC-SIGN 
(hDC-SIGN) since feline DC-SIGN (fDC-SIGN) had yet to be characterized.  
However a search of recently available genomic shotgun sequencing data identified 
fDC-SIGN (Appendix 1).  Studies on the interactions of FIPV and fDC-SIGN are 
likely to yield interesting results in the future.   
In addition to facilitating the systemic spread of FIPV, dendritic cells may also 
play a key role in outcome of disease.  Dendritic cells control the type of T-helper cell 
differentiation (Th1 vs. Th2) in vivo by means of cytokine production (9).  As 
previously discussed, the type of immune response mounted against feline coronavirus 
infection has a decisive role in the eventual outcome of disease.  Therefore FIPV-
infected dendritic cells are likely to play a vital role in FIP pathogenesis early during 
infection.  Examination of the cytokines produced by FIPV-infected dendritic cells in 
vitro may illuminate the contribution of these cells in controlling the T-helper cell 
differentiation. 
  
5.3 Potential treatment strategies for FIP   
 FIP is a significant disease of domestic cats, with some populations seeing 
disease incidence up to a 12%, depending on breed and age (2).  There are currently 
no effective treatments for FIP, and euthanasia is recommended for cats with the 
disease (1).  The development of an effective vaccine has proven elusive.  Early 
vaccine candidates were found to enhance disease, rather than prevent it, by the 
process of antibody-dependent enhancement of macrophage infection (15).  Currently 
there is only one licensed vaccine on the market called Primucell FIP (Pfizer), 
however its use is not recommended by the American Association of Feline 
Practitioners Feline Vaccine Advisory Panel (1).  The vaccine is a live-modified 
temperature sensitive vaccine based on a serotype 2 feline coronavirus, and therefore 
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does not cross-protect against the more common serotype 1 strains (15).  In addition, 
the vaccine cannot be administered until 16 weeks of age, when most kittens are 
already seropositive for feline coronavirus (15).  Depending on disease severity, 
treatment may be attempted with immunosuppressants such as glucocorticoids and 
cyclophosphamide, however this will not prevent an eventual fatal outcome (1).   
This thesis identifies and characterizes two specific targets which could be 
explored for their potential therapeutic value in patients with FIP.  The first target is 
cathepsin B, which is shown here to be required for infection by feline coronaviruses.  
This work demonstrates that the feline coronavirus spike protein is cleaved during 
cellular entry by cathepsin B (catB), and that inhibiting this protease blocks viral 
infection in primary immune cells.  If a cat diagnosed with FIP were treated with a 
general cysteine protease inhibitor (e.g. E-64-d), or a specific catB inhibitor (e.g. 
CA074-Me), it might inhibit viral infection.  If infection was halted, the use of 
conjunctive immunosuppressive therapy might then be able to treat the underlying 
disease process, and allow damaged tissue to heal.  Multiple studies have documented 
the efficacy and safety of these cathepsin protease inhibitors in mice (5, 7, 10, 13, 14, 
21, 22, 24).  In fact, treatment of infected mice with the cysteine protease inhibitor E-
64-d has been shown to switch the host immune response from a Th2 antibody-
mediated response, to a Th1 cell-mediated response (13).  This is noteworthy 
considering that a strong Th1 response has been correlated with immunity to FIP; 
while a strong Th2 response has been correlated with the development of FIP (15).   
Another potential therapeutic target to explore is the activation of p38 MAPK 
in FIPV-infected immune cells.  It is shown in this thesis that FIPV activates the p38 
MAPK signaling pathway in immune cells, resulting in the production of the pro-
inflammatory cytokines TNFα and IL-1β.  The specific p38 MAPK inhibitors used in 
this study have been shown to be efficacious and nontoxic in vivo (19, 28).  If a cat 
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diagnosed with FIP were treated with a p38 inhibitor (e.g. SC-409), this may reduce 
the amount of pro-inflammatory cytokines produced in the patient.  In combination 
with immunosuppressive therapy, or an anti-viral such as E-64-d, this treatment may 
have potential therapeutic value in cats with FIP.   
Pre-clinical toxicity and pharmacokinetic analyses are planned in cats to 
demonstrate the efficacy and safety of E-64-d, CA074-Me, and SC-409.  Oral, 
subcutaneous, intramuscular, and intravenous methods of administration will be 
tested.  If no toxicity is observed, and the inhibitors are bioactive in vivo, then double-
blinded placebo controlled studies will be conducted with SPF cats experimentally 
infected with FIPV.  Cats would be treated with either cathepsin inhibitor, p38 MAPK 
inhibitor, both, or placebo, with or without conjunctive immunosuppressive therapy.  
The development and severity of disease would be monitored to determine the 
therapeutic value of these treatments.  If any of these treatments are successful in 
alleviating disease in an experimental infection, then patients with confirmed cases of 
FIP (by immunofluorescent staining of primary monocytes) at the Cornell University 
Hospital could be enrolled for a clinical trial. 
 In summation, the difficulty in treating FIP is akin to that of human 
immunodeficiency virus (HIV) in humans.  Both diseases are caused by a virus with 
100% mortality rates, and both have proven refractive to the development of an 
effective vaccine.  In the case of HIV, treatment has defaulted to an array of antivirals 
(including protease inhibitors) which have been applied with varying degrees of 
success at prolonging and improving the quality of life for patients.  This may be the 
best approach for the treatment of cats with FIP.  The novel treatment strategies 
recommended in this thesis may improve the quality of life in cats with FIP, and at 
best, could completely alleviate disease. 
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APPENDIX 1 
 
IDENTIFICATION OF FELINE DC-SIGN 
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Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin 
(DC-SIGN), also known as CD209, is a C-type lectin expressed on the surface of a 
variety of immune cells.  DC-SIGN non-specifically binds glycosylated proteins in a 
calcium-dependent manner, and is an integral part of the immune system’s ability to 
sample the host environment.  It is conserved in a wide range of mammals including 
humans and other primates, dogs, pigs, cows, horses and mice.  DC-SIGN has not 
been identified in felines; however both feline immunodeficiency virus (FIV) and 
feline infectious peritonitis virus (FIPV) have been shown to interact with human DC-
SIGN (hDC-SIGN) in vitro.   
Shotgun sequencing data of the feline genome has recently been released at 2X 
coverage, though annotation has yet to be completed.  In order to identify feline DC-
SIGN (fDC-SIGN), feline genomic sequence was analyzed using the NCBI BLAST 
search engine with the canine DC-SIGN sequence as a template.  From this search the 
feline DC-SIGN gene was assembled with 98% intron coverage from 4 sections of 
shotgun sequencing data (gb|ACBE01052350.1| Felis catus c495301847.Contig1b10, 
gb|AANG01184685.1| Felis catus cont1.184684, gb|ACBE01052349.1| Felis catus 
c448001196.Contig1, gb|AANG01554893.1| Felis catus cont1.554892).  Reverse-
transcription PCR (RT-PCR) primers were designed from this sequence (5’fDCSIGN-
fwd: ATGTGTGACCCCAAGGAGCCGGAT, and 3’fDCSIGN-rev: TCAGAGGCC 
CGGGCAGGGGGACGA).  Primary feline blood mononuclear cells were isolated as 
previously described and RNA was extracted using the QIAGEN RNA extraction kit 
as specified by the manufacturer.  RT-PCR yielded a 0.8 kb band which was 
subsequently cloned into pTOPO2.1.  Sequencing using the pTOPO universal primers 
T7 and SP6 confirmed the identity of the band as feline DC-SIGN (Figure A1.1).   
fDC-SIGN is most closely related to canine DC-SIGN (85.7%), porcine DC-
SIGN (62.5%), bovine DC-SIGN (62.5%) and equine DC-SIGN (59.4%) (Figure 
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A1.3A).  fDC-SIGN shares only 41.8% homology with hDC-SIGN (Figure A1.3A).  
Similar to other DC-SIGN sequences which have been reported, fDC-SIGN possesses 
eight conserved cysteines, and nine acidic amino acids involved in calcium binding 
(Figure A1.2).   
The fDC-SIGN gene was subcloned into the pEF4-myc-his vector, and then 
subcloned into the mammalian expression vector pCDNA3.1 while retaining the C-
terminal myc tag.  fDC-SIGN-myc was expressed in murine NIH-3T3 cells using 
lipofectamine transfection (Figure A1.4).    Studies are currently underway to examine 
the role of fDC-SIGN in the entry of FIPV. 
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Figure A1.1 The nucleotide and amino acid sequence of feline DC-SIGN.  The 
nucleotide sequence of feline DC-SIGN (fDC-SIGN) is shown as the top line in 
regular font.  The amino acid sequence of fDC-SIGN is shown as the bottom line in 
bolded font.  The transmembrane domain is boxed, and the glycan binding domain is 
underlined. 
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Figure A1.2 Alignment of DC-SIGN sequences.  fDC-SIGN is shown aligned with 
significant DC-SIGN sequences from other mammals.  Also shown are the conserved 
cysteines (*), and the amino acids involved in the first (1) and second (2) calcium-
binding sites.  
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Figure A1.3 Phylogenetic analyses of feline DC-SIGN.  A phylogenetic tree of DC-
SIGN seqeuences generated by Clustal W allignemnt (A).  The percent homology 
between fDC-SIGN and other mammalian DC-SIGN sequences is shown (B). 
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Figure A1.4 Expression of feline DC-SIGN.  pCDNA3.1-fDCSIGN-myc was 
transfected in NIH-3T3 cells using lipofectamine.  Cells were fixed with 
paraformaldehyde and stained with mouse anti-myc (9E10), and anti-mouse alexfuor 
488.  fDC-SIGN expression was visualized by immunofluorescent microscopy. 
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 APPENDIX TWO 
 
SEROTYPE 1 FIPV UTLIZES CATHEPSIN B AND DC-SIGN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
132 
 
 In chapters three and four it is shown the serotype 2 feline coronaviruses 
(FCoV-2) utilize cathepsin B (catB) and DC-SIGN for cellular entry in cultured and 
primary cells.  However FCoV-2 make up only a small amount of field isolates. 
Serotype 1 feline coronaviruses (FCoV-1) comprise up to 80% of field isolates, 
however they are difficult (but not impossible) to isolate and grow in culture.  
A series of limited experiments with FCoV-1 were carried out in order to 
determine if they also rely on cathepsins and DC-SIGN.  As shown in figure A2.1, 
serotype 1 FIPV-BLACK infection is dependent on catB, but independent of cathepsin 
L (catL) and low pH.  The same characteristics were observed for FIPV-UCD2 (data 
not shown).  It was also investigated whether FCoV-1 utilize DC-SIGN.  As shown in 
figure A2.2, both FIPV-BLACK and FIPV-UCD2 infection is significantly enhanced 
by DC-SIGN expression.  This suggests that although serotype 1 and 2 feline 
coronaviruses possess markedly different spike proteins, they are likely to utilize 
similar cellular entry pathways.  Even more significant, this suggests that both 
serotypes would be susceptible to cathepsin inhibitors. 
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Figure A2.1 Serotype 1 feline coronavirus FIPV-BLACK requires cathepsin B 
for infection.  AKD cells were pretreated with either cathepsin B inhibitor (CA074-
Me), cathepsin L inhibitor (Z-FY-(t-Bu)-DMK), the lysomotrophic agent NH4Cl, or 
DMSO (control).  After 2 hours they were infected with FIPV-BLACK and incubated 
at 37ºC for 12 hours.  Cells were then fixed in paraformaldehyde and stained with 
feline anti-FIP-1 antisera and anti-feline FITC.   
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Figure A2.2 Serotype 1 feline coronaviruses FIPV-BLACK and FIPV-UCD2 
utilize DC-SIGN for infection.  CRFK cells and CRFK cells transfected with human 
DC-SIGN (hDC-SIGN) were infected with either FIPV-BLACK (A) or FIPV-UCD2 
(B).  Cells were incubated for 12 hours at 37ºC, fixed in paraformaldehyde, and 
stained with feline anti-FIP-1 antisera and anti-feline FITC.  
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 APPENDIX THREE 
 
CANINE AND PORCINE CORONAVIRUSES UTILIZE CATHEPSIN B 
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  The spike protein of serotype 2 canine coronavirus (CCoV-2) and 
transmissible gastroenteritis virus (TGEV) share extensive homology with that of 
serotype 2 feline coronavirus (FCoV-2).  As shown in chapter four, the spike protein 
of FCoV-2 is dependent on proteolytic activation by cathepsin B (catB).  It was 
therefore investigated whether CCoV-2 and TGEV are also dependent on catB for 
infection.  As shown in figure A3.1, infection by CCoV-2 and TGEV are both blocked 
by the catB inhibitor CA074-Me. 
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Figure A3.1 Infection by CCoV-2 and TGEV is dependent on cathepsin B.  A72 
cells were pretreated with either cathepsin B inhibitor (CA074-Me), or DMSO 
(control).  After 2 hours they were infected with either CCoV-171 or TGEV-Purdue 
and incubated at 37ºC for 8 hours.  Cells were then fixed in paraformaldehyde and 
stained with mouse anti-spike 18A7.4 and anti-mouse alexfluor 488.   
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